human
cathepsin
l
belong
cathepsin
famili
proteolyt
enzym
primarili
endopeptidas
activ
although
primari
function
origin
thought
housekeep
enzym
degrad
intracellular
endocytos
protein
lysosom
numer
recent
studi
suggest
play
mani
critic
specif
role
divers
cellular
set
surprisingli
dysregul
function
cathepsin
l
manifest
sever
human
diseas
make
attract
target
drug
develop
unfortun
sever
redund
isoformspecif
function
recent
emerg
ad
complex
drug
discoveri
process
address
seri
chemic
biolog
tool
develop
help
defin
cathepsin
l
biolog
exquisit
precis
specif
cellular
context
review
elabor
recent
develop
small
molecul
inhibitor
probe
human
cathepsin
l
outlin
mechan
action
describ
potenti
util
dissect
unknown
function
molecul
also
well
establish
subject
eleg
review
elsewher
unfortun
sever
overlap
redund
function
cathepsin
l
also
emerg
therefor
critic
import
function
biolog
normal
diseasespecif
cell
type
clearli
annot
signific
resourc
direct
drug
discoveri
endeavor
review
briefli
outlin
biogenesi
cathepsin
l
describ
posttransl
process
traffick
highlight
key
structur
featur
requir
format
activ
matur
cathepsin
l
brief
summari
cathepsin
l
biolog
role
human
diseas
provid
next
final
detail
uptod
report
exist
cathepsin
ltarget
small
molecul
inhibitor
function
probe
mechanist
detail
describ
human
cathepsin
l
gene
cthl
uniprot
primari
access
number
locat
posit
chromosom
encod
total
amino
acid
peptid
sequenc
mw
kda
code
space
includ
region
ntermin
signal
peptid
two
propeptid
two
matur
peptid
compris
heavi
h
chain
light
l
chain
figur
transcript
signal
peptid
cotransl
remov
polysom
result
kda
procathepsin
l
transloc
endoplasm
reticulum
undergo
nlink
glycosyl
mannos
rich
sugar
mannos
sugar
procathepsin
l
phosphoryl
ci
golgi
udpnacetylglucosamin
nacetylglucosaminephosphotransferas
enzym
receptor
locat
surfac
tran
golgi
network
recogn
peptid
deliv
procathepsin
l
peptid
lysosom
via
endolysosom
pathway
weakli
acid
environ
endosomelysosom
releas
receptor
phosphat
group
mannos
sugar
remov
lysosom
acid
phosphatas
activ
matur
cathepsin
l
form
occur
remov
propeptid
either
autocatalysi
aspartyl
cathepsin
acid
environ
lysosom
lead
doubl
chain
form
matur
activ
cathepsin
l
compris
h
l
domain
connect
disulfid
bridg
figur
note
sever
isoform
cathepsin
l
also
observ
specif
cell
type
due
altern
splice
mrna
transcript
altern
translat
molecul
varieti
highli
invas
form
cancer
also
well
establish
subject
eleg
review
elsewher
unfortun
sever
overlap
redund
function
cathepsin
l
also
emerg
therefor
critic
import
function
biolog
normal
diseasespecif
cell
type
clearli
annot
signific
resourc
direct
drug
discoveri
endeavor
review
briefli
outlin
biogenesi
cathepsin
l
describ
posttransl
process
traffick
highlight
key
structur
featur
requir
format
activ
matur
cathepsin
l
brief
summari
cathepsin
l
biolog
role
human
diseas
provid
next
final
detail
uptod
report
exist
cathepsin
ltarget
small
molecul
inhibitor
function
probe
mechanist
detail
describ
human
cathepsin
l
gene
cthl
uniprot
primari
access
number
locat
posit
chromosom
encod
total
amino
acid
peptid
sequenc
mw
kda
code
space
includ
region
ntermin
signal
peptid
two
propeptid
two
matur
peptid
compris
heavi
h
chain
light
l
chain
figur
transcript
signal
peptid
cotransl
remov
polysom
result
kda
procathepsin
l
transloc
endoplasm
reticulum
undergo
nlink
glycosyl
mannos
rich
sugar
mannos
sugar
procathepsin
l
phosphoryl
ci
golgi
udpnacetylglucosamin
nacetylglucosaminephosphotransferas
enzym
receptor
locat
surfac
tran
golgi
network
recogn
peptid
deliv
procathepsin
l
peptid
lysosom
via
endolysosom
pathway
weakli
acid
environ
endosomelysosom
releas
receptor
phosphat
group
mannos
sugar
remov
lysosom
acid
phosphatas
activ
matur
cathepsin
l
form
occur
remov
propeptid
either
autocatalysi
aspartyl
cathepsin
acid
environ
lysosom
lead
doubl
chain
form
matur
activ
cathepsin
l
compris
h
l
domain
connect
disulfid
bridg
figur
note
sever
isoform
cathepsin
l
also
observ
specif
cell
type
due
altern
splice
mrna
transcript
altern
translat
recombin
cathepsin
l
propeptid
nm
ph
cystatin
nm
cystatin
b
nm
cystatin
c
nm
cystatin
nm
mhc
class
ii
molecul
pm
lkinenogen
pm
cystatin
f
nm
sialostatin
l
pm
antimicrobi
peptid
nm
molecul
differ
form
cathepsin
l
enzym
isol
distinct
cell
type
intracellular
extracellular
environ
specif
cellular
locat
seem
play
pivot
role
wide
rang
function
activ
addit
degrad
cellular
protein
endolysosom
pathway
cathepsin
l
also
particip
autophag
degrad
pathway
specif
degrad
two
autophagosom
marker
gabarapii
special
podocyt
cell
kidney
play
critic
role
retent
variou
protein
requir
maintain
blood
plasma
shown
cytoplasm
variant
activ
cathepsin
l
degrad
two
key
protein
gtpase
dynamin
synaptopodin
requir
podocyt
proper
glomerular
filtrat
function
consist
higher
podocyt
cathepsin
l
express
found
varieti
proteinur
kidney
diseas
function
inhibit
eg
creat
cathepsin
l
resist
dynamin
led
revers
symptom
interestingli
nuclear
isoform
cathepsin
l
associ
anoth
uniqu
function
kidney
cell
involv
proteolyt
process
cell
cycl
regulatori
transcript
factor
promot
cell
prolifer
polycyst
kidney
diseas
pkd
inde
mous
model
pkd
lower
level
nuclear
cathepsin
l
corel
increas
level
protein
cyst
anoth
type
cell
cathepsin
l
seem
play
major
role
maintain
homeostasi
cardiomyocyt
earli
investig
stypmann
et
al
year
old
mice
show
develop
mani
key
trait
dilat
cardiomyopathi
interstiti
myocardi
fibrosi
cardiac
chamber
dilat
impair
contract
addit
newborn
mice
acquir
increas
number
acid
organel
although
alter
morpholog
function
studi
indic
inhibit
cathepsin
l
activ
cell
detriment
proper
function
cardiac
cell
corrobor
overexpress
studi
cathepsin
l
mice
cardiomyocyt
exhibit
cardioprotect
effect
inhibit
akt
signal
pathway
function
secret
extracellular
cathepsin
l
cardiac
remodel
repair
also
studi
extens
sinc
known
mani
protein
extracellular
matrix
ecm
also
physiolog
substrat
cathepsin
l
includ
laminin
collagen
type
iv
xviii
ischem
heart
diseas
major
risk
factor
diabet
patient
unabl
maintain
sugar
level
effici
cardiac
repair
endotheli
progenitor
cell
contain
elev
level
cathepsin
l
home
ischem
cell
initi
process
neovascular
uncontrol
diabet
condit
howev
cathepsin
l
function
ecm
space
neovascular
significantli
impair
hamper
ischem
repair
process
control
releas
trypsinogen
pancreat
acinar
cell
subsequ
activ
duodenum
critic
import
event
must
tightli
regul
dysregul
releas
activ
trypsin
result
acut
pancreat
condit
cathepsin
b
effici
cleav
trypsinogen
produc
enhanc
level
activ
trypsin
promot
pancreat
cathepsin
l
act
regulatori
brake
keep
activ
process
control
cleav
trypsinogen
distinct
site
amino
acid
c
termin
cathepsin
b
therebi
inactiv
trypsinogen
consist
mice
show
increas
trypsin
activ
pancrea
surprisingli
reduc
pancreat
due
diminish
inflamm
effect
attribut
due
enhanc
apoptosi
acinar
cell
vs
necrosi
neuroand
immunobiolog
cathepsin
l
import
document
role
well
exampl
regul
secretori
vesicl
neuroendocrin
system
chromaffin
granul
hous
mani
matur
functionreadi
enkephalin
opioid
peptid
upon
appropri
signal
stimuli
activ
enkephalin
neuropeptid
secret
releas
impart
analges
immunecel
specif
function
studi
yasothornsrikul
et
al
reveal
cathepsin
l
proteolyt
process
enzym
render
activ
metenkephalin
proenkephalin
anoth
studi
sever
symptom
due
antigeninduc
arthriti
aai
significantli
reduc
mice
due
weaken
helper
cell
popul
thymu
molecul
express
cathepsin
l
highli
dysregul
sever
human
diseas
includ
diabet
aai
abdomin
aortic
aneurysm
liver
fibrosi
cancer
involv
numer
form
highli
invas
cancer
particularli
noteworthi
cover
great
detail
recent
review
earli
studi
gottesman
reveal
extracellular
cathepsin
l
level
increas
transform
cell
ecm
environ
rapidli
degrad
sever
structur
compon
significantli
increas
migratoryinvas
potenti
cell
promot
metastasi
surprisingli
cathepsin
l
inhibit
small
molecul
consid
viabl
strategi
develop
novel
anticanc
agent
small
molecul
inhibitor
lysosom
play
critic
role
human
biolog
receiv
traffick
process
degrad
biolog
molecul
semin
cellular
process
endocytosi
phagocytosi
autophagi
secret
discov
groundbreak
work
de
duve
singlemembran
enclos
cytosol
organel
maintain
acid
ph
environ
hous
close
sixti
proteolyt
enzym
among
eleven
member
cystein
cathepsin
enzym
versatil
express
function
profil
cathepsin
l
b
c
f
h
k
v
x
w
enzym
close
mimic
clan
papain
structur
catalyt
cycl
mediat
numer
crucial
cellular
event
exampl
particip
process
involv
cell
death
protein
degrad
posttransl
modif
protein
extracellular
matrix
ecm
remodel
autophagi
immun
signal
given
function
aberrantli
dysregul
sever
human
diseas
mani
consid
prime
target
therapeut
develop
sever
eleg
review
recent
emerg
describ
import
cystein
cathepsin
normal
physiolog
human
diseas
focu
review
specif
human
cathepsin
l
ubiquit
express
endopeptidas
whose
involv
sever
human
diseas
emerg
recent
year
includ
liver
fibrosi
type
ii
diabet
cardiac
bone
immun
kidney
disord
addit
role
wide
varieti
highli
invas
form
cancer
propeptid
act
import
regulatori
onoff
switch
well
fold
catalyst
cathepsin
activ
surprisingli
natur
propeptid
among
cystein
cathepsin
highli
diverg
chain
length
primari
sequenc
thought
uniqu
function
relev
given
ubiquit
presenc
tissu
allow
select
suppress
enzym
activ
henc
unintend
autoactiv
transport
propeptid
act
import
regulatori
onoff
switch
well
fold
catalyst
cathepsin
activ
surprisingli
natur
propeptid
among
cystein
cathepsin
highli
diverg
chain
length
primari
sequenc
thought
uniqu
function
relev
given
ubiquit
presenc
tissu
allow
select
suppress
enzym
activ
henc
unintend
autoactiv
transport
endolysosom
compart
molecul
cathepsin
l
two
inhibitori
propeptid
one
contain
amino
acid
contain
amino
acid
exist
crystal
structur
human
procathepsin
l
reveal
amino
acid
inhibitori
propeptid
chain
span
opposit
direct
substrat
bind
form
sever
highaffin
noncoval
interact
surround
residu
activ
site
interestingli
opposit
direct
bind
inhibitori
propeptid
segment
evolutionarili
conserv
member
cystein
cathepsin
includ
cathepsin
b
molecul
endolysosom
compart
cathepsin
l
two
inhibitori
propeptid
one
contain
amino
acid
contain
amino
acid
exist
crystal
structur
human
procathepsin
l
reveal
amino
acid
inhibitori
propeptid
chain
span
opposit
direct
substrat
bind
form
sever
highaffin
noncoval
interact
surround
residu
activ
site
interestingli
opposit
direct
bind
inhibitori
propeptid
segment
evolutionarili
conserv
member
cystein
cathepsin
includ
cathepsin
b
biogenesi
human
cathepsin
l
full
length
cathepsin
l
mrna
transcrib
translat
ribosom
follow
fulllength
peptid
enter
ribosomesbound
endoplasm
reticulum
lumen
signal
peptid
remov
procathepsin
l
enter
golgi
network
undergo
nlink
glycosyl
follow
mannos
phosphoryl
format
appropri
disulfid
linkag
last
step
modifi
procathepsin
l
shuttl
lysosom
endolysosom
pathway
gener
doubl
chain
form
activ
matur
human
cathepsin
l
domin
pathway
regul
activ
matur
cathepsin
l
endogen
protein
inhibitor
cystatin
like
propeptid
compet
physiolog
substrat
bind
enzym
activ
site
tabl
interestingli
protein
inhibitori
agent
cathepsin
l
also
report
organ
exampl
kotsyfaki
et
al
report
exist
two
cathepsin
l
inhibitori
protein
carrier
main
vector
lyme
diseasecarri
parasit
ixodu
scapulari
name
abil
specif
inhibit
cathepsin
l
nm
ki
pm
activ
sialostatin
l
abrog
protect
proteolyt
activ
host
cell
infest
site
therebi
promot
tick
surviv
addit
also
possess
potent
antiinflammatori
immunosuppress
activ
inhibit
cytotox
killer
cell
full
length
cathepsin
l
mrna
transcrib
translat
ribosom
follow
fulllength
peptid
enter
ribosomesbound
endoplasm
reticulum
lumen
signal
peptid
remov
procathepsin
l
enter
golgi
network
undergo
nlink
glycosyl
follow
mannos
phosphoryl
format
appropri
disulfid
linkag
last
step
modifi
procathepsin
l
shuttl
lysosom
endolysosom
pathway
gener
doubl
chain
form
activ
matur
human
cathepsin
l
domin
pathway
regul
activ
matur
cathepsin
l
endogen
protein
inhibitor
cystatin
like
propeptid
compet
physiolog
substrat
bind
enzym
activ
site
tabl
interestingli
protein
inhibitori
agent
cathepsin
l
also
report
organ
exampl
kotsyfaki
et
al
report
exist
two
cathepsin
l
inhibitori
protein
carrier
main
vector
lyme
diseasecarri
parasit
ixodu
scapulari
name
abil
specif
inhibit
cathepsin
l
ic
nm
k
pm
activ
sialostatin
l
abrog
protect
proteolyt
activ
host
cell
infest
site
therebi
promot
tick
surviv
addit
also
possess
potent
antiinflammatori
immunosuppress
activ
inhibit
cytotox
killer
cell
tabl
report
physiolog
inhibitori
ligand
human
cathepsin
l
inhibit
constant
year
sever
class
physiolog
synthet
inhibitor
discov
target
cathepsin
l
herein
focu
nonphysiolog
inhibitor
could
broadli
classifi
revers
irrevers
inhibitor
revers
irrevers
inhibitor
could
distinguish
mean
mechanist
approach
util
enzym
inactiv
revers
inhibitor
gener
engag
target
protein
use
noncoval
interact
howev
certain
case
form
quasicoval
bond
eventu
disengag
activ
site
say
upon
dilut
irrevers
inhibitor
hand
perman
modifi
protein
interest
via
format
stabl
coval
bond
revers
irrevers
inhibitor
pro
con
gener
believ
revers
inhibitor
prefer
candid
drug
discoveri
irrevers
inhibitor
due
advers
immun
respons
howev
sever
exampl
success
drug
use
clinic
work
irrevers
inhibitori
mechan
irrevers
inhibitor
also
wide
util
function
biolog
eg
develop
activitybas
probe
major
synthet
cathepsin
l
inhibitor
recogniz
peptid
sequenc
often
deriv
physiolog
substrat
bind
activ
site
protein
often
contain
strateg
place
electrophil
warhead
trap
nucleophil
residu
figur
activ
knowledg
enzym
structur
associ
substrat
specif
thu
play
import
role
design
select
inhibitor
cathepsin
semin
studi
choe
et
al
studi
substrat
specif
use
highli
diversifi
posit
scan
synthet
combinatori
librari
compris
fluorogen
tetrapeptid
allow
differenti
individu
enzym
bind
propens
base
distinct
amino
acid
prefer
capit
strategi
success
develop
select
substrat
substratebas
inhibitor
cathepsin
k
import
contribut
understand
subsit
bind
prefer
cathepsin
l
enzym
stem
sever
time
crystal
structur
studi
help
reveal
key
differ
structur
landscap
enzym
subsit
import
studi
shenoy
et
al
solv
crystal
structur
ligand
bound
cathepsin
l
document
structur
composit
ligand
bind
site
figur
analysi
zphetyr
otertbutyl
c
c
h
bound
cathepsin
l
reveal
subsit
rel
wide
unrestrict
compos
b
subsit
guid
associ
form
aromat
cluster
accommod
tertbutyl
group
c
side
chain
help
form
subsit
engag
nonpolar
interact
phenyl
side
chain
final
carboxybenzyl
group
find
interact
residu
subsit
figur
howev
turn
differ
ligand
may
find
slightli
alter
bind
interact
enzym
subsit
depend
structur
featur
exampl
shenoy
et
al
show
although
zphetyr
otertbutyl
dmk
bind
subsit
cathepsin
l
observ
zphetyr
otertbutyl
c
c
h
ligand
find
altern
interact
residu
activ
site
pocket
find
corrobor
studi
well
suggest
structur
featur
ligand
influenc
subsit
composit
cathepsin
l
enzym
inform
duli
capit
develop
differ
class
inhibitor
discuss
next
follow
section
discuss
type
cathepsin
ltarget
chemotyp
util
develop
small
molecul
inhibitor
avail
univers
cathepsin
inhibitor
class
show
margin
select
toward
cathepsin
l
compar
cathepsin
b
moder
select
cathepsin
h
report
barrett
et
al
although
develop
sever
synthet
analog
improv
potenc
lack
desir
select
toward
cathepsin
l
propos
probabl
bind
orient
follow
nonsubstratelik
orient
ie
occupi
nonprim
site
figur
enzym
pocket
phe
arg
cbz
amc
sh
key
subsiteform
amino
acid
residu
correspond
number
shown
blue
wherea
catalyt
diad
form
residu
depict
red
author
use
file
construct
figur
anoth
studi
goursalin
et
al
report
number
epoxysuccinyl
amino
acid
benzyl
ester
systemat
vari
amino
acid
attach
epoxid
ring
intend
investig
effect
determin
select
toward
cathepsin
l
result
surprisingli
indic
specif
analog
follow
trend
gener
observ
substrat
possibl
due
like
bind
orient
enzym
pocket
among
cathepsin
l
compar
cathepsin
b
moder
select
cathepsin
h
report
barrett
et
al
although
develop
sever
synthet
analog
improv
potenc
lack
desir
select
toward
cathepsin
l
propos
probabl
bind
orient
follow
nonsubstratelik
orient
ie
occupi
nonprim
site
figur
enzym
pocket
phe
arg
cbz
amc
sh
key
subsiteform
amino
acid
residu
correspond
number
shown
blue
wherea
catalyt
diad
form
residu
depict
red
author
use
file
construct
figur
anoth
studi
goursalin
et
al
report
number
epoxysuccinyl
amino
acid
benzyl
ester
systemat
vari
amino
acid
attach
epoxid
ring
intend
investig
effect
determin
select
toward
cathepsin
l
result
surprisingli
indic
specif
analog
follow
trend
gener
observ
substrat
possibl
due
like
bind
orient
enzym
pocket
among
key
subsiteform
amino
acid
residu
correspond
number
shown
blue
wherea
catalyt
diad
form
residu
depict
red
author
use
file
construct
figur
epoxysuccin
inhibitor
histor
play
crucial
role
deciph
cystein
proteas
biolog
class
compound
contain
epoxid
ring
electrophil
warhead
trap
activ
site
catalyt
cystein
residu
protein
ltransepoxysuccinylleucylamido
butan
entri
tabl
perhap
studi
commerci
avail
univers
cathepsin
inhibitor
class
show
margin
select
toward
cathepsin
l
compar
cathepsin
b
moder
select
cathepsin
h
report
barrett
et
al
although
develop
sever
synthet
analog
improv
potenc
lack
desir
select
toward
cathepsin
l
propos
probabl
bind
orient
follow
nonsubstratelik
orient
ie
occupi
nonprim
site
figur
enzym
pocket
anoth
studi
goursalin
et
al
report
number
epoxysuccinyl
amino
acid
benzyl
ester
systemat
vari
amino
acid
attach
epoxid
ring
intend
investig
effect
determin
select
toward
cathepsin
l
result
surprisingli
indic
specif
analog
follow
trend
gener
observ
substrat
possibl
due
like
bind
orient
enzym
pocket
among
synthes
compound
katunuma
clik
help
comput
model
base
stereostructur
three
develop
clik
inhibitor
hydrolyt
stabl
show
highli
select
inhibit
hepat
cathepsin
l
vivo
elucid
inhibit
mechan
class
compound
base
crystal
structur
entri
tabl
complex
crystal
structur
reveal
unlik
bind
prime
nonprim
site
activ
site
pocket
notabl
specif
toward
cathepsin
l
attribut
exist
phenylalanin
residu
site
hydrophob
interact
mediat
ntermin
pyridin
ring
figur
class
alkyl
agent
initi
play
import
role
deciph
mechanist
aspect
cathepsin
inhibit
peptidyldiazomethan
entri
tabl
peptidylchloromethan
entri
tabl
crawford
et
al
report
highli
potent
inhibitor
two
chemotyp
span
activ
site
show
signific
select
improv
cystein
proteas
howev
class
inhibitor
suffer
stabil
issu
found
limit
util
vivo
assay
peptidylhydroxylamin
first
introduc
mechanismbas
inhibitor
serin
cystein
proteinas
bromm
et
al
adapt
scaffold
prepar
librari
npeptidyloacyl
hydroxylamin
exhibit
rapid
select
inactiv
sever
lysosom
cystein
proteinas
class
inhibitor
occupi
activ
site
enzym
irrevers
inactiv
cystein
cathepsin
free
enzym
activ
recov
enzymeinhibitor
complex
expos
exhaust
ultrafiltr
enzymefre
inhibitor
ratio
chromatographi
sephadex
among
develop
inhibitor
zphephenhoma
entri
tabl
inhibit
cathepsin
l
potenc
show
signific
select
cathepsin
cathepsin
b
respect
interestingli
stabil
efficaci
class
inhibitor
determin
natur
substitut
hydroxylamin
oxygen
electronwithdraw
tendenc
show
posit
correl
inactiv
kinet
although
class
inhibitor
exhibit
desir
trait
respect
potenc
select
suffer
majorli
aqueou
stabil
issu
halfliv
rang
min
aqueou
solut
anoth
studi
bromm
et
al
develop
seri
npeptidyloacyl
hydroxam
lysin
posit
improv
inhibitori
profil
cystein
proteas
serin
counterpart
maximum
inhibit
observ
zphelysnhonbz
entri
tabl
select
cathepsin
select
cathepsin
b
author
postul
activ
site
cy
residu
attack
carbonyl
hydroxam
form
tetrahedr
intermedi
wherea
nitrogen
hydroxam
primarili
remain
deproton
pka
presum
engag
electrostat
interact
activ
site
residu
figur
inhibitor
provid
option
vari
leav
group
target
site
hydrophob
substitu
prefer
posit
comparison
kiki
valu
inactiv
exhibit
follow
trend
aa
gli
ala
val
leu
phe
nitrophenyl
analog
entri
tabl
incur
hydrophob
electronwithdraw
properti
exert
maximum
potenc
select
cathepsin
l
test
cystein
proteas
hydrophob
substitu
prefer
posit
comparison
kiki
valu
inactiv
exhibit
follow
trend
aa
gli
ala
val
leu
phe
nitrophenyl
analog
entri
tabl
incur
hydrophob
electronwithdraw
properti
exert
maximum
potenc
select
cathepsin
l
test
cystein
proteas
hydrophob
substitu
prefer
posit
comparison
kiki
valu
inactiv
exhibit
follow
trend
aa
gli
ala
val
leu
phe
nitrophenyl
analog
entri
tabl
incur
hydrophob
electronwithdraw
properti
exert
maximum
potenc
select
cathepsin
l
test
cystein
proteas
followup
studi
bromm
et
al
synthes
test
seri
new
inhibitor
gener
formula
zpheglynhocoaa
aa
amino
acid
papain
class
enzym
class
inhibitor
coval
modifi
activesit
cy
residu
via
sulfenamid
like
npeptidyloacyl
hydroxam
counterpart
shown
mass
spectrometr
analysi
inhibitor
provid
option
vari
leav
group
target
site
hydrophob
substitu
prefer
posit
comparison
kiki
valu
inactiv
exhibit
follow
trend
aa
gli
ala
val
leu
phe
nitrophenyl
analog
entri
tabl
incur
hydrophob
electronwithdraw
properti
exert
maximum
potenc
select
cathepsin
l
test
cystein
proteas
followup
studi
bromm
et
al
synthes
test
seri
new
inhibitor
gener
formula
zpheglynhocoaa
aa
amino
acid
papain
class
enzym
class
inhibitor
coval
modifi
activesit
cy
residu
via
sulfenamid
like
npeptidyloacyl
hydroxam
counterpart
shown
mass
spectrometr
analysi
inhibitor
provid
option
vari
leav
group
target
site
hydrophob
substitu
prefer
posit
comparison
k
k
valu
inactiv
exhibit
follow
trend
aa
gli
ala
val
leu
phe
ph
nitrophenyl
analog
entri
tabl
incur
hydrophob
electronwithdraw
properti
exert
maximum
potenc
select
cathepsin
l
test
cystein
proteas
anoth
class
peptidyl
inhibitor
span
activ
site
util
catalyt
machineri
cathepsin
l
effect
attenu
enzym
activ
peptidyl
acyloxymethan
krantz
et
al
develop
librari
inhibitori
compound
gener
sequenc
zphexch
ocor
systemat
vari
amino
acid
residu
denot
x
denot
r
posit
among
synthes
compound
zpheci
sbn
ch
cf
ph
entri
tabl
exhibit
almost
diffusioncontrol
inactiv
kinet
toward
cathepsin
l
howev
show
margin
select
cathepsin
b
cathepsin
analyz
structureact
relationship
librari
author
elucid
import
site
cathepsin
l
could
potenti
use
har
select
among
cystein
cathepsin
separ
studi
torkar
et
al
design
librari
peptid
cathepsin
l
span
activ
site
attenu
enzym
activ
via
noncoval
interact
initi
evalu
compound
activ
cathepsin
l
cathepsin
b
compar
hit
cathepsin
k
author
discov
five
select
noncoval
peptidyl
inhibitor
cathepsin
l
transform
irrevers
inhibitor
strateg
append
electrophil
warhead
figur
acyloxymethyl
keton
aomk
group
entri
tabl
howev
attach
aomk
group
drastic
impact
select
profil
inhibitor
suggest
import
adjuv
effect
prime
site
target
determin
efficaci
select
class
compound
class
inhibitor
found
widespread
util
detect
proteas
activ
util
develop
activitybas
probe
discuss
later
section
interest
class
inhibitor
concept
deriv
peptidyl
aziridin
martichonok
et
al
develop
seri
aziridin
deriv
test
papain
cathepsin
l
b
contrarili
l
diastereom
potent
isom
aziridin
analog
exhibit
opposit
trend
still
inactiv
enzym
importantli
efficaci
class
inhibitor
strongli
phdepend
show
maxim
inhibitori
potenc
attribut
proton
form
aziridin
ring
suscept
nucleophil
attack
catalyt
cy
residu
among
develop
librari
ho
azleunhiam
entri
tabl
analog
exhibit
maxim
inhibitori
potenc
toward
cathepsin
l
moder
select
cathepsin
b
correspond
l
isom
ho
l
azleunhiam
entri
almost
less
activ
maintain
similar
trend
gener
sinc
proton
form
aziridin
ring
undergo
nucleophil
attack
presum
involv
water
moleculemedi
ringopen
like
epoxid
counterpart
although
promis
full
potenti
class
compound
could
presum
achiev
ph
aziridin
ring
nitrogen
get
complet
proton
class
inhibitor
thu
lack
practic
util
catalyt
cystein
cathepsin
l
start
lose
activ
ph
major
cellbas
assay
perform
mostli
ph
higher
notabl
studi
schirmeist
et
al
develop
three
differ
class
inhibitor
acid
azi
electrophil
warhead
instal
differ
posit
peptid
chain
figur
perform
thorough
sar
analysi
type
inhibitor
exhibit
timedepend
irrevers
inactiv
cathepsin
l
norecoveri
enzym
activ
even
extens
dialysi
enzymeinhibitor
complex
among
typei
inhibitor
nacyl
aziridin
aziridin
ctermin
amino
acid
mixtur
diastereomer
peptid
procathepsin
b
sequenc
leuglygli
entri
tabl
exhibit
enhanc
inhibit
toward
cathepsin
l
attribut
overal
uniqu
fold
cathepsin
l
shallow
pocket
due
presenc
addit
residu
type
ii
class
inhibitor
figur
resembl
classic
aziridin
scaffold
nunsubstitut
aziridin
aziridin
ntermin
amino
acid
analog
nitrogen
aziridin
remain
unsubstitut
among
type
ii
inhibitor
test
eto
r
r
azileuobzl
entri
tabl
inactiv
cathepsin
l
higher
secondord
rate
constant
eto
azileuobzl
although
latter
show
better
select
cathepsin
b
interest
class
inhibitor
concept
deriv
peptidyl
aziridin
martichonok
et
al
develop
seri
aziridin
deriv
test
papain
cathepsin
l
b
contrarili
l
diastereom
potent
isom
aziridin
analog
exhibit
opposit
trend
still
inactiv
enzym
importantli
efficaci
class
inhibitor
strongli
phdepend
show
maxim
inhibitori
potenc
attribut
proton
form
aziridin
ring
suscept
nucleophil
attack
catalyt
cy
residu
among
develop
librari
ho
azleunhiam
entri
tabl
analog
exhibit
maxim
inhibitori
potenc
toward
cathepsin
l
moder
select
cathepsin
b
correspond
l
isom
ho
l
azleunhiam
entri
almost
less
activ
maintain
similar
trend
gener
sinc
proton
form
aziridin
ring
undergo
nucleophil
attack
presum
involv
water
moleculemedi
ringopen
like
epoxid
counterpart
although
promis
full
potenti
class
compound
could
presum
achiev
ph
aziridin
ring
nitrogen
get
complet
proton
class
inhibitor
thu
lack
practic
util
catalyt
cystein
cathepsin
l
start
lose
activ
ph
major
cellbas
assay
perform
mostli
ph
higher
notabl
studi
schirmeist
et
al
develop
three
differ
class
inhibitor
acid
azi
electrophil
warhead
instal
differ
posit
peptid
chain
figur
perform
thorough
sar
analysi
type
inhibitor
exhibit
timedepend
irrevers
inactiv
cathepsin
l
norecoveri
enzym
activ
even
extens
dialysi
enzymeinhibitor
complex
among
typei
inhibitor
nacyl
aziridin
aziridin
ctermin
amino
acid
mixtur
diastereomer
peptid
procathepsin
b
sequenc
leuglygli
entri
tabl
exhibit
enhanc
inhibit
toward
cathepsin
l
attribut
overal
uniqu
fold
cathepsin
l
shallow
pocket
due
presenc
addit
residu
type
ii
class
inhibitor
figur
resembl
classic
aziridin
scaffold
nunsubstitut
aziridin
aziridin
ntermin
amino
acid
analog
nitrogen
aziridin
remain
unsubstitut
among
type
ii
inhibitor
test
eto
r
r
azileuobzl
entri
tabl
inactiv
cathepsin
l
higher
secondord
rate
constant
eto
azileuobzl
although
latter
show
better
select
cathepsin
b
type
iii
inhibitor
class
figur
compris
nacyl
bispeptidyl
deriv
aziridin
aziridin
ring
rest
middl
peptid
bocph
r
r
eto
azileuproobzl
entri
tabl
seri
potent
analog
howev
exhibit
margin
select
cathepsin
b
diminish
eudysm
ratio
author
superimpos
analyz
structur
certain
epoxid
aziridin
postul
inhibitor
assum
differ
orient
activ
site
still
bind
within
enzym
pocket
scaffold
explor
vicik
et
al
extend
previou
work
develop
seri
compound
boc
leu
azi
azi
obn
figur
type
analog
span
pocket
inactiv
cathepsin
l
select
cathepsin
b
motif
also
use
affin
label
cathepsin
l
discuss
later
section
class
compound
especi
nunsubstitut
aziridinyl
peptid
special
case
nacyl
one
exhibit
high
select
potenc
provid
premis
develop
chemic
biolog
tool
much
need
function
studi
tabl
seri
potent
analog
howev
exhibit
margin
select
cathepsin
b
diminish
eudysm
ratio
author
superimpos
analyz
structur
certain
epoxid
aziridin
postul
inhibitor
assum
differ
orient
activ
site
still
bind
within
enzym
pocket
scaffold
explor
vicik
et
al
extend
previou
work
develop
seri
compound
boc
leu
azi
azi
obn
figur
type
analog
span
pocket
inactiv
cathepsin
l
select
cathepsin
b
motif
also
use
affin
label
cathepsin
l
discuss
later
section
class
compound
especi
nunsubstitut
aziridinyl
peptid
special
case
nacyl
one
exhibit
high
select
potenc
provid
premis
develop
chemic
biolog
tool
much
need
function
studi
anoth
promis
scaffold
act
michael
acceptor
hijack
catalyt
residu
cystein
cathepsin
peptidyl
aryl
vinylsulfon
scaffold
first
introduc
palmer
et
al
irrevers
inhibitor
cystein
cathepsin
subsequ
extend
studi
perform
sar
analysi
class
inhibitor
show
pancathepsin
inhibit
tabl
seri
potent
analog
howev
exhibit
margin
select
cathepsin
b
diminish
eudysm
ratio
author
superimpos
analyz
structur
certain
epoxid
aziridin
postul
inhibitor
assum
differ
orient
activ
site
still
bind
within
enzym
pocket
scaffold
explor
vicik
et
al
extend
previou
work
develop
seri
compound
boc
leu
azi
azi
obn
figur
type
analog
span
pocket
inactiv
cathepsin
l
select
cathepsin
b
motif
also
use
affin
label
cathepsin
l
discuss
later
section
class
compound
especi
nunsubstitut
aziridinyl
peptid
special
case
nacyl
one
exhibit
high
select
potenc
provid
premis
develop
chemic
biolog
tool
much
need
function
studi
anoth
promis
scaffold
act
michael
acceptor
hijack
catalyt
residu
cystein
cathepsin
peptidyl
aryl
vinylsulfon
scaffold
first
introduc
palmer
et
al
irrevers
inhibitor
cystein
cathepsin
subsequ
extend
studi
perform
sar
analysi
class
inhibitor
show
pancathepsin
inhibit
occasion
select
toward
cathepsin
certain
scaffold
howev
separ
studi
mendieta
et
al
author
develop
structur
novel
librari
twenti
peptidyl
vinylsulfon
figur
introduc
extens
divers
posit
subsequ
also
vari
posit
keep
either
morpholin
nmethyl
piperazin
group
intact
dock
studi
activ
select
inhibitor
entri
anoth
promis
scaffold
act
michael
acceptor
hijack
catalyt
residu
cystein
cathepsin
peptidyl
aryl
vinylsulfon
scaffold
first
introduc
palmer
et
al
irrevers
inhibitor
cystein
cathepsin
subsequ
extend
studi
perform
sar
analysi
class
inhibitor
show
pancathepsin
inhibit
occasion
select
toward
cathepsin
certain
scaffold
howev
separ
studi
mendieta
et
al
author
develop
structur
novel
librari
twenti
peptidyl
vinylsulfon
figur
introduc
extens
divers
r
posit
subsequ
also
vari
r
posit
keep
either
morpholin
nmethyl
piperazin
group
intact
dock
studi
activ
select
inhibitor
entri
tabl
class
reveal
inhibitor
extend
site
cathepsin
l
moieti
resid
close
proxim
residu
therebi
favor
format
michael
adduct
author
postul
consid
efficaci
peptidyl
aryl
vinyl
sulfon
strong
anticanc
candid
could
har
cultiv
scaffold
tabl
class
reveal
inhibitor
extend
site
cathepsin
l
moieti
resid
close
proxim
residu
therebi
favor
format
michael
adduct
author
postul
consid
efficaci
peptidyl
aryl
vinyl
sulfon
strong
anticanc
candid
could
har
cultiv
scaffold
one
potent
class
inhibitor
also
includ
michael
acceptor
peptidyl
aryl
vinylsulfon
ester
superior
michael
acceptor
vinyl
sulfon
serv
potent
inhibitor
cruzaina
parasit
cystein
proteas
cruzi
homolog
cathepsin
l
scaffold
explor
dana
et
al
determin
superior
aryl
vinylsulfon
ester
aryl
vinylsulfon
aryl
vinylsulfonamid
counterpart
toward
cathepsin
l
inhibit
thu
synthes
screen
efficaci
librari
aryl
vinylsulfon
ester
compound
cathepsin
l
phenyl
vinylsulfon
found
champion
ligand
presum
due
favor
interact
phenyl
moieti
prime
site
residu
cathepsin
l
design
hybrid
inhibitor
entri
tabl
strateg
append
vinylsulfon
moieti
electrophil
warhead
modestli
potent
revers
cathepsin
l
inhibitor
design
base
hypothesi
develop
compound
target
prime
site
nonprim
site
residu
interact
inde
exhibit
almost
diffusioncontrol
inactiv
kinet
maintain
excel
select
profil
toward
cathepsin
l
figur
furthermor
cellperm
inhibit
intracellular
activ
cathepsin
l
human
breast
cancer
cell
line
also
enhanc
integr
cellcel
junction
effect
attenu
migratori
potenti
cell
demonstr
scratch
assay
author
anticip
class
inhibitor
may
find
extens
usag
deciph
contextspecif
cathepsin
l
biolog
one
potent
class
inhibitor
also
includ
michael
acceptor
peptidyl
aryl
vinylsulfon
ester
superior
michael
acceptor
vinyl
sulfon
serv
potent
inhibitor
cruzaina
parasit
cystein
proteas
cruzi
homolog
cathepsin
l
scaffold
explor
dana
et
al
determin
superior
aryl
vinylsulfon
ester
aryl
vinylsulfon
aryl
vinylsulfonamid
counterpart
toward
cathepsin
l
inhibit
thu
synthes
screen
efficaci
librari
aryl
vinylsulfon
ester
compound
cathepsin
l
phenyl
vinylsulfon
found
champion
ligand
presum
due
favor
interact
phenyl
moieti
prime
site
residu
cathepsin
l
design
hybrid
inhibitor
entri
tabl
strateg
append
vinylsulfon
moieti
electrophil
warhead
modestli
potent
revers
cathepsin
l
inhibitor
design
base
hypothesi
develop
compound
target
prime
site
nonprim
site
residu
interact
inde
exhibit
almost
diffusioncontrol
inactiv
kinet
maintain
excel
select
profil
toward
cathepsin
l
figur
furthermor
cellperm
inhibit
intracellular
activ
cathepsin
l
human
breast
cancer
cell
line
also
enhanc
integr
cellcel
junction
effect
attenu
migratori
potenti
cell
demonstr
scratch
assay
author
anticip
class
inhibitor
may
find
extens
usag
deciph
contextspecif
cathepsin
l
biolog
molecul
tabl
class
reveal
inhibitor
extend
site
cathepsin
l
moieti
resid
close
proxim
residu
therebi
favor
format
michael
adduct
author
postul
consid
efficaci
peptidyl
aryl
vinyl
sulfon
strong
anticanc
candid
could
har
cultiv
scaffold
one
potent
class
inhibitor
also
includ
michael
acceptor
peptidyl
aryl
vinylsulfon
ester
superior
michael
acceptor
vinyl
sulfon
serv
potent
inhibitor
cruzaina
parasit
cystein
proteas
cruzi
homolog
cathepsin
l
scaffold
explor
dana
et
al
determin
superior
aryl
vinylsulfon
ester
aryl
vinylsulfon
aryl
vinylsulfonamid
counterpart
toward
cathepsin
l
inhibit
thu
synthes
screen
efficaci
librari
aryl
vinylsulfon
ester
compound
cathepsin
l
phenyl
vinylsulfon
found
champion
ligand
presum
due
favor
interact
phenyl
moieti
prime
site
residu
cathepsin
l
design
hybrid
inhibitor
entri
tabl
strateg
append
vinylsulfon
moieti
electrophil
warhead
modestli
potent
revers
cathepsin
l
inhibitor
design
base
hypothesi
develop
compound
target
prime
site
nonprim
site
residu
interact
inde
exhibit
almost
diffusioncontrol
inactiv
kinet
maintain
excel
select
profil
toward
cathepsin
l
figur
furthermor
cellperm
inhibit
intracellular
activ
cathepsin
l
human
breast
cancer
cell
line
also
enhanc
integr
cellcel
junction
effect
attenu
migratori
potenti
cell
demonstr
scratch
assay
author
anticip
class
inhibitor
may
find
extens
usag
deciph
contextspecif
cathepsin
l
biolog
recent
anoth
interest
discoveri
provid
wealth
inform
cathepsin
linhibitor
interact
came
marin
cyanobacteri
extract
miller
et
al
first
report
gallinamid
potent
irrevers
inhibitor
cathepsin
l
ic
valu
nm
greater
select
cathepsin
v
b
respect
perform
molecular
dock
molecular
dynam
simul
learn
peptidyl
backbon
inhibitor
span
activ
site
wherea
side
chain
engag
favor
interact
differ
activ
site
pocket
place
michael
acceptor
enamid
close
proxim
catalyt
cy
residu
followup
studi
boudreau
et
al
perform
molecular
dock
studi
predict
potenti
modif
gallinamid
scaffold
would
har
favor
enzymeinhibitor
interact
enabl
develop
compound
improv
inhibitori
efficaci
synthes
panel
compound
retain
gallinamid
vari
amino
acid
posit
figur
led
discoveri
potent
analog
seri
entri
tabl
subnanomolar
ic
valu
pm
fast
time
depend
inactiv
kinet
suggest
improv
bind
reactiv
inhibitor
enzym
activ
site
author
found
class
compound
effect
inactiv
cruzain
homolog
cystein
proteas
cruzi
use
cellbas
assay
gallinamid
analog
thu
provid
remark
inhibitori
scaffold
could
potenti
har
build
select
enzym
inhibitor
varieti
therapeut
applic
recent
anoth
interest
discoveri
provid
wealth
inform
cathepsin
linhibitor
interact
came
marin
cyanobacteri
extract
miller
et
al
first
report
gallinamid
potent
irrevers
inhibitor
cathepsin
l
valu
nm
greater
select
cathepsin
v
b
respect
perform
molecular
dock
molecular
dynam
simul
learn
peptidyl
backbon
inhibitor
span
activ
site
wherea
side
chain
engag
favor
interact
differ
activ
site
pocket
place
michael
acceptor
enamid
close
proxim
catalyt
cy
residu
followup
studi
boudreau
et
al
perform
molecular
dock
studi
predict
potenti
modif
gallinamid
scaffold
would
har
favor
enzymeinhibitor
interact
enabl
develop
compound
improv
inhibitori
efficaci
synthes
panel
compound
retain
gallinamid
vari
amino
acid
posit
figur
led
discoveri
potent
analog
seri
entri
tabl
subnanomolar
valu
pm
fast
time
depend
inactiv
kinet
suggest
improv
bind
reactiv
inhibitor
enzym
activ
site
author
found
class
compound
effect
inactiv
cruzain
homolog
cystein
proteas
cruzi
use
cellbas
assay
gallinamid
analog
thu
provid
remark
inhibitori
scaffold
could
potenti
har
build
select
enzym
inhibitor
varieti
therapeut
applic
figur
gallinamid
reconstruct
alter
amino
acid
sequenc
posit
acryl
group
michael
acceptor
shown
red
one
classic
inhibitor
use
long
period
time
dissect
cystein
proteinas
activ
leupeptin
microbi
product
leupeptin
peptidyl
aldehyd
occupi
activ
site
cleft
cystein
cathepsin
form
thiohemiacet
intermedi
trap
catalyt
cystein
residu
complex
hydrolyz
time
thu
show
coval
revers
natur
inhibitor
figur
leupeptin
unfortun
suffer
nonspecif
inhibit
serin
cystein
proteinas
thu
make
unfavor
clinic
usag
chemic
biolog
applic
issu
howev
address
woo
et
al
design
synthes
six
peptidyl
aldehyd
analog
potent
leupeptin
nm
exhibit
improv
select
toward
cathepsin
l
cathepsin
b
calpain
ii
potent
cathepsin
l
inhibitor
seri
zphepheh
nm
figur
show
select
cathepsin
b
interestingli
data
demonstr
import
aromat
amino
acid
phenylalanin
tyrosin
posit
determin
potenc
select
toward
cathepsin
l
oalkyl
tyrosin
group
diminish
inhibitori
effici
zphetyr
bu
h
nm
followup
public
test
efficaci
zphetyrh
nm
select
cathepsin
b
figur
vitro
vivo
compound
effect
inhibit
parathyroid
hormonestimul
osteoclast
bone
resorpt
pit
format
assay
suppress
bone
weight
loss
ovariectom
mous
dosedepend
manner
administ
intraperiton
figur
gallinamid
reconstruct
alter
amino
acid
sequenc
posit
acryl
group
michael
acceptor
shown
red
one
classic
inhibitor
use
long
period
time
dissect
cystein
proteinas
activ
leupeptin
microbi
product
leupeptin
peptidyl
aldehyd
occupi
activ
site
cleft
cystein
cathepsin
form
thiohemiacet
intermedi
trap
catalyt
cystein
residu
complex
hydrolyz
time
thu
show
coval
revers
natur
inhibitor
figur
leupeptin
unfortun
suffer
nonspecif
inhibit
serin
cystein
proteinas
thu
make
unfavor
clinic
usag
chemic
biolog
applic
issu
howev
address
woo
et
al
design
synthes
six
peptidyl
aldehyd
analog
potent
leupeptin
ic
nm
exhibit
improv
select
toward
cathepsin
l
cathepsin
b
calpain
ii
potent
cathepsin
l
inhibitor
seri
zphepheh
ic
nm
figur
show
select
cathepsin
b
interestingli
data
demonstr
import
aromat
amino
acid
phenylalanin
tyrosin
posit
determin
potenc
select
toward
cathepsin
l
oalkyl
tyrosin
group
diminish
inhibitori
effici
zphetyr
bu
h
ic
nm
followup
public
test
efficaci
zphetyrh
ic
nm
select
cathepsin
b
figur
vitro
vivo
compound
effect
inhibit
parathyroid
hormonestimul
osteoclast
bone
resorpt
pit
format
assay
suppress
bone
weight
loss
ovariectom
mous
dosedepend
manner
administ
intraperiton
anoth
interest
studi
yasuma
et
al
develop
librari
compound
vari
amino
acid
substitu
posit
inhibitor
carri
thorough
sar
studi
studi
reveal
configur
stereogen
center
sconfigur
favor
rconfigur
posit
steric
factor
key
inhibitori
efficaci
appar
substitu
posit
interact
posit
residu
rather
proper
stereogen
allow
placement
inhibitor
vicin
catalyt
cystein
residu
interact
subsit
cathepsin
l
hand
prefer
hydrophob
moderates
group
alkyl
chain
bulkier
group
like
phenylalanin
favor
subsit
show
prefer
hydrophob
bulki
moieti
substitu
among
synthes
compound
n
nm
select
cathepsin
b
figur
attenu
releas
ca
hydroxyprolin
bone
vitro
bone
cultur
system
restrict
bone
loss
ovariectom
mice
dose
oral
modif
scaffold
report
lyna
et
al
author
design
develop
diand
tripeptidyl
base
substrat
inhibitor
specif
profil
cathepsin
l
compound
zphetyr
obut
cocho
entri
tabl
turn
highli
potent
select
inhibitor
cathepsin
l
ki
valu
nm
molecul
adapt
shenoy
et
al
assess
structur
basi
cathepsin
l
inhibit
studi
author
crystal
glyoxal
inhibitor
cathepsin
l
form
tetrahedr
thiohemiacet
oxygen
atom
stabil
oxyanion
hole
tyr
obut
group
found
occupi
site
phenyl
carboxybenzyl
group
occupi
site
respect
class
inhibitor
success
deploy
function
biolog
cathepsin
l
azepanonebas
compound
first
report
oral
bioavail
extrem
potent
inhibitor
cathepsin
k
shown
pharmacokinet
studi
rat
marqui
et
al
subsequ
adopt
templat
extend
work
acquir
select
inhibitor
cathepsin
l
similar
potenc
class
inhibitor
armor
keto
function
group
anoth
interest
studi
yasuma
et
al
develop
librari
compound
vari
amino
acid
substitu
posit
inhibitor
carri
thorough
sar
studi
studi
reveal
configur
stereogen
center
sconfigur
favor
rconfigur
posit
steric
factor
key
inhibitori
efficaci
appar
substitu
posit
interact
posit
residu
rather
proper
stereogen
allow
placement
inhibitor
vicin
catalyt
cystein
residu
interact
subsit
cathepsin
l
hand
prefer
hydrophob
moderates
group
alkyl
chain
bulkier
group
like
phenylalanin
favor
subsit
show
prefer
hydrophob
bulki
moieti
substitu
among
synthes
compound
n
ic
nm
select
cathepsin
b
figur
attenu
releas
ca
hydroxyprolin
bone
vitro
bone
cultur
system
restrict
bone
loss
ovariectom
mice
dose
oral
anoth
interest
studi
yasuma
et
al
develop
librari
compound
vari
amino
acid
substitu
posit
inhibitor
carri
thorough
sar
studi
studi
reveal
configur
stereogen
center
sconfigur
favor
rconfigur
posit
steric
factor
key
inhibitori
efficaci
appar
substitu
posit
interact
posit
residu
rather
proper
stereogen
allow
placement
inhibitor
vicin
catalyt
cystein
residu
interact
subsit
cathepsin
l
hand
prefer
hydrophob
moderates
group
alkyl
chain
bulkier
group
like
phenylalanin
favor
subsit
show
prefer
hydrophob
bulki
moieti
substitu
among
synthes
compound
n
nm
select
cathepsin
b
figur
attenu
releas
ca
hydroxyprolin
bone
vitro
bone
cultur
system
restrict
bone
loss
ovariectom
mice
dose
oral
modif
scaffold
report
lyna
et
al
author
design
develop
diand
tripeptidyl
base
substrat
inhibitor
specif
profil
cathepsin
l
compound
zphetyr
obut
cocho
entri
tabl
turn
highli
potent
select
inhibitor
cathepsin
l
ki
valu
nm
molecul
adapt
shenoy
et
al
assess
structur
basi
cathepsin
l
inhibit
studi
author
crystal
glyoxal
inhibitor
cathepsin
l
form
tetrahedr
thiohemiacet
oxygen
atom
stabil
oxyanion
hole
tyr
obut
group
found
occupi
site
phenyl
carboxybenzyl
group
occupi
site
respect
class
inhibitor
success
deploy
function
biolog
cathepsin
l
azepanonebas
compound
first
report
oral
bioavail
extrem
potent
inhibitor
cathepsin
k
shown
pharmacokinet
studi
rat
marqui
et
al
subsequ
adopt
templat
extend
work
acquir
select
inhibitor
cathepsin
l
similar
potenc
class
inhibitor
armor
keto
function
group
figur
n
orient
activ
site
cathepsin
l
find
favor
interact
within
pocket
enzym
modif
scaffold
report
lyna
et
al
author
design
develop
diand
tripeptidyl
base
substrat
inhibitor
specif
profil
cathepsin
l
compound
zphetyr
obut
cocho
entri
tabl
turn
highli
potent
select
inhibitor
cathepsin
l
k
valu
nm
molecul
adapt
shenoy
et
al
assess
structur
basi
cathepsin
l
inhibit
studi
author
crystal
glyoxal
inhibitor
cathepsin
l
form
tetrahedr
thiohemiacet
oxygen
atom
stabil
oxyanion
hole
tyr
obut
group
found
occupi
site
phenyl
carboxybenzyl
group
occupi
site
respect
class
inhibitor
success
deploy
function
biolog
cathepsin
l
azepanonebas
compound
first
report
oral
bioavail
extrem
potent
inhibitor
cathepsin
k
shown
pharmacokinet
studi
rat
marqui
et
al
subsequ
adopt
templat
extend
work
acquir
select
inhibitor
cathepsin
l
similar
potenc
class
inhibitor
armor
keto
function
group
act
electrophil
warhead
trap
cystein
proteas
form
transient
coval
bond
activesit
cy
residu
render
inactiv
enzym
author
initi
work
scrupul
studi
cathepsin
kinhibitor
complex
reveal
influenc
substitu
inhibitor
determin
efficaci
select
profil
compound
base
observ
design
synthes
seri
compound
secur
highli
potent
cathepsin
l
inhibitor
k
app
nm
entri
tabl
exert
remark
select
cathepsin
k
fairli
modest
select
cathepsin
b
interestingli
sar
show
replac
leucin
benzofuran
cathepsin
k
inhibitor
bulkier
hydrophob
aromat
group
yield
improv
potenc
select
toward
cathepsin
l
figur
molecular
dock
studi
support
observ
cathepsin
k
found
shallow
pocket
cathepsin
l
thu
incorpor
bulkier
napthyl
group
posit
favor
cathepsin
l
inhibit
cathepsin
k
hand
inclus
anoth
napthyl
group
posit
promot
steric
clash
rather
further
desir
hydrophob
interact
within
pocket
cathepsin
k
thu
incur
better
select
profil
toward
cathepsin
l
cathepsin
k
templat
proven
import
tool
studi
cystein
cathepsin
extend
achiev
potent
cathepsin
sselect
inhibitor
cellular
activ
molecul
act
electrophil
warhead
trap
cystein
proteas
form
transient
coval
bond
activesit
cy
residu
render
inactiv
enzym
author
initi
work
scrupul
studi
cathepsin
kinhibitor
complex
reveal
influenc
substitu
inhibitor
determin
efficaci
select
profil
compound
base
observ
design
synthes
seri
compound
secur
highli
potent
cathepsin
l
inhibitor
ki
app
nm
entri
tabl
exert
remark
select
cathepsin
k
fairli
modest
select
cathepsin
b
interestingli
sar
show
replac
leucin
benzofuran
cathepsin
k
inhibitor
bulkier
hydrophob
aromat
group
yield
improv
potenc
select
toward
cathepsin
l
figur
molecular
dock
studi
support
observ
cathepsin
k
found
shallow
pocket
cathepsin
l
thu
incorpor
bulkier
napthyl
group
posit
favor
cathepsin
l
inhibit
cathepsin
k
hand
inclus
anoth
napthyl
group
posit
promot
steric
clash
rather
further
desir
hydrophob
interact
within
pocket
cathepsin
k
thu
incur
better
select
profil
toward
cathepsin
l
cathepsin
k
templat
proven
import
tool
studi
cystein
cathepsin
extend
achiev
potent
cathepsin
sselect
inhibitor
cellular
activ
nitril
group
contain
inhibitor
wide
recogn
coval
revers
inhibitor
certain
class
enzym
depend
cysteinemedi
nucleophil
attack
catalysi
nitril
residu
trap
sulfur
form
thioimid
bond
figur
hydrolyz
time
render
free
enzym
odanacatib
one
prime
exampl
class
compound
evalu
clinic
agent
although
limit
success
nitril
tunabl
target
engag
natur
scaffold
adapt
target
relev
enzym
includ
cathepsin
hardegg
et
al
util
nitril
warhead
examin
effect
halogen
bond
proteinligand
interact
develop
seri
compound
perform
thorough
sar
analysi
nitril
electrophil
face
toward
site
trap
catalyt
cystein
develop
analog
substitu
occupi
site
systemat
vari
strateg
alter
substitu
paraposit
phenyl
group
figur
author
observ
improv
inhibit
profil
placement
halogen
paraposit
phenyl
ring
follow
trend
cl
br
entri
tabl
f
substitu
outlier
analysi
enzymeinhibitor
cocryst
structur
reveal
halogen
para
posit
phenyl
ring
suitabl
interact
site
fluorin
analog
point
away
avoid
electron
repuls
oxygen
lone
pair
author
also
perform
comput
analysi
taken
togeth
crystal
nitril
group
contain
inhibitor
wide
recogn
coval
revers
inhibitor
certain
class
enzym
depend
cysteinemedi
nucleophil
attack
catalysi
nitril
residu
trap
sulfur
form
thioimid
bond
figur
hydrolyz
time
render
free
enzym
odanacatib
one
prime
exampl
class
compound
evalu
clinic
agent
although
limit
success
nitril
tunabl
target
engag
natur
scaffold
adapt
target
relev
enzym
includ
cathepsin
hardegg
et
al
util
nitril
warhead
examin
effect
halogen
bond
proteinligand
interact
develop
seri
compound
perform
thorough
sar
analysi
nitril
electrophil
face
toward
site
trap
catalyt
cystein
develop
analog
substitu
occupi
site
systemat
vari
strateg
alter
substitu
paraposit
phenyl
group
figur
author
observ
improv
inhibit
profil
placement
halogen
paraposit
phenyl
ring
follow
trend
cl
br
entri
tabl
f
substitu
outlier
analysi
enzymeinhibitor
cocryst
structur
reveal
halogen
para
posit
phenyl
ring
suitabl
interact
site
fluorin
analog
point
away
avoid
electron
repuls
oxygen
lone
pair
author
also
perform
comput
analysi
taken
togeth
crystal
data
suggest
xc
angl
distanc
interact
atom
primarili
influenc
proteinligand
interact
work
provid
import
roadmap
develop
improv
chemic
biolog
tool
halogenprotein
interact
success
util
molecul
data
suggest
xc
angl
distanc
interact
atom
primarili
influenc
proteinligand
interact
work
provid
import
roadmap
develop
improv
chemic
biolog
tool
halogenprotein
interact
success
util
examin
effect
interact
may
chalcogen
bond
pocket
cathepsin
l
giroud
et
al
util
triazinenitril
scaffold
author
synthes
divers
set
triazinenitril
compound
diversifi
heteroaren
target
pocket
substitu
kept
constant
among
develop
compound
librari
analog
entri
tabl
exhibit
maximum
inhibitori
potenti
similar
geometri
also
follow
similar
inhibitori
pattern
figur
molecular
model
base
cocryst
structur
show
favor
chalcogen
interact
backbon
carbonyl
angl
pocket
support
conform
strain
analysi
chalcogenenzym
interact
compens
higher
torsion
strain
scontain
ligand
compar
benzofuranyl
imidazopyridinyl
ligand
studi
demonstr
import
intermolecular
interact
conform
strain
assess
effect
heterobicycl
ligand
pocket
could
potenti
util
develop
cathepsin
l
select
inhibitor
data
suggest
xc
angl
distanc
interact
atom
primarili
influenc
proteinligand
interact
work
provid
import
roadmap
develop
improv
chemic
biolog
tool
halogenprotein
interact
success
util
examin
effect
interact
may
chalcogen
bond
pocket
cathepsin
l
giroud
et
al
util
triazinenitril
scaffold
author
synthes
divers
set
triazinenitril
compound
diversifi
heteroaren
target
pocket
substitu
kept
constant
among
develop
compound
librari
analog
entri
tabl
exhibit
maximum
inhibitori
potenti
similar
geometri
also
follow
similar
inhibitori
pattern
figur
molecular
model
base
cocryst
structur
show
favor
chalcogen
interact
backbon
carbonyl
angl
pocket
support
conform
strain
analysi
chalcogenenzym
interact
compens
higher
torsion
strain
scontain
ligand
compar
benzofuranyl
imidazopyridinyl
ligand
studi
demonstr
import
intermolecular
interact
conform
strain
assess
effect
heterobicycl
ligand
pocket
could
potenti
util
develop
cathepsin
l
select
inhibitor
examin
effect
interact
may
chalcogen
bond
pocket
cathepsin
l
giroud
et
al
util
triazinenitril
scaffold
author
synthes
divers
set
triazinenitril
compound
diversifi
heteroaren
target
pocket
substitu
kept
constant
among
develop
compound
librari
analog
entri
tabl
exhibit
maximum
inhibitori
potenti
similar
geometri
also
follow
similar
inhibitori
pattern
figur
molecular
model
base
cocryst
structur
show
favor
chalcogen
interact
backbon
carbonyl
angl
pocket
support
conform
strain
analysi
chalcogenenzym
interact
compens
higher
torsion
strain
scontain
ligand
compar
benzofuranyl
imidazopyridinyl
ligand
studi
demonstr
import
intermolecular
interact
conform
strain
assess
effect
heterobicycl
ligand
pocket
could
potenti
util
develop
cathepsin
l
select
inhibitor
subsequ
studi
kuhn
et
al
systemat
compar
effect
four
differ
approach
select
medicin
chemist
b
manual
model
c
dock
follow
manual
filter
free
energi
calcul
fep
systemat
protocol
enabl
priorit
build
block
effect
target
cathepsin
l
enzym
author
develop
seri
analog
vari
substitu
keep
fix
figur
analyz
affin
enzym
kinet
found
fep
method
superior
wellestablish
methodolog
method
predict
relev
ligand
also
identifi
topolog
requir
substitu
effect
engag
pocket
among
develop
compound
cyclopentylmethyl
substitu
pocket
entri
tabl
incur
favor
interact
optim
fill
front
part
pocket
strategi
certainli
provid
edg
convent
methodolog
predict
optim
ligand
pocket
target
find
could
benefit
ongo
effort
achiev
suitabl
therapeut
candid
cathepsin
l
enzym
benzofuranyl
similar
geometri
also
follow
similar
inhibitori
pattern
figur
molecular
model
base
cocryst
structur
show
favor
chalcogen
interact
backbon
carbonyl
angl
pocket
support
conform
strain
analysi
chalcogenenzym
interact
compens
higher
torsion
strain
scontain
ligand
compar
benzofuranyl
imidazopyridinyl
ligand
studi
demonstr
import
intermolecular
interact
conform
strain
assess
effect
heterobicycl
ligand
pocket
could
potenti
util
develop
cathepsin
l
select
inhibitor
subsequ
studi
kuhn
et
al
systemat
compar
effect
four
differ
approach
select
medicin
chemist
b
manual
model
c
dock
follow
manual
filter
free
energi
calcul
fep
systemat
protocol
enabl
priorit
build
block
effect
target
cathepsin
l
enzym
author
develop
seri
analog
vari
substitu
keep
fix
figur
analyz
affin
enzym
kinet
found
fep
method
superior
wellestablish
methodolog
method
predict
relev
ligand
also
identifi
topolog
requir
substitu
effect
engag
pocket
among
develop
compound
cyclopentylmethyl
substitu
pocket
entri
tabl
incur
favor
interact
optim
fill
front
part
pocket
strategi
certainli
provid
edg
convent
methodolog
predict
optim
ligand
pocket
target
find
could
benefit
ongo
effort
achiev
suitabl
therapeut
candid
cathepsin
l
enzym
thiosemicarbazon
moieti
first
recogn
relev
coval
revers
warhead
cathepsin
l
homolog
enzym
cruzain
proteas
cruzi
mechan
inactivact
involv
format
transient
coval
bond
catalyt
cy
residu
figur
interest
studi
kishor
kumar
et
al
first
util
idea
synthes
small
librari
compound
activ
class
inhibitor
compris
one
metabromo
substitut
aryl
ring
along
anoth
one
optim
substitut
function
inhibitor
place
activ
site
cleft
cathepsin
l
metabromo
substitut
aryl
ring
occupi
site
thiosemicarbazon
motif
lie
near
activ
site
cystein
howev
motif
extend
captur
site
interact
place
arylalkyl
group
termin
nitrogen
thiosemicarbazon
inhibitori
potenc
complet
diminish
overal
class
inhibitor
show
good
select
cathepsin
b
exhibit
low
cytotox
test
human
cancer
cell
line
follow
studi
kishor
et
al
parker
et
al
expand
scope
thiosemicarbazon
scaffold
develop
divers
thiosemicarbazon
moieti
first
recogn
relev
coval
revers
warhead
cathepsin
l
homolog
enzym
cruzain
proteas
cruzi
mechan
inactivact
involv
format
transient
coval
bond
catalyt
cy
residu
figur
interest
studi
kishor
kumar
et
al
first
util
idea
synthes
small
librari
compound
activ
class
inhibitor
compris
one
metabromo
substitut
aryl
ring
along
anoth
one
optim
substitut
function
inhibitor
place
activ
site
cleft
cathepsin
l
metabromo
substitut
aryl
ring
occupi
site
thiosemicarbazon
motif
lie
near
activ
site
cystein
molecul
subsequ
studi
kuhn
et
al
systemat
compar
effect
four
differ
approach
select
medicin
chemist
b
manual
model
c
dock
follow
manual
filter
free
energi
calcul
fep
systemat
protocol
enabl
priorit
build
block
effect
target
cathepsin
l
enzym
author
develop
seri
analog
vari
substitu
keep
fix
figur
analyz
affin
enzym
kinet
found
fep
method
superior
wellestablish
methodolog
method
predict
relev
ligand
also
identifi
topolog
requir
substitu
effect
engag
pocket
among
develop
compound
cyclopentylmethyl
substitu
pocket
entri
tabl
incur
favor
interact
optim
fill
front
part
pocket
strategi
certainli
provid
edg
convent
methodolog
predict
optim
ligand
pocket
target
find
could
benefit
ongo
effort
achiev
suitabl
therapeut
candid
cathepsin
l
enzym
thiosemicarbazon
moieti
first
recogn
relev
coval
revers
warhead
cathepsin
l
homolog
enzym
cruzain
proteas
cruzi
mechan
inactivact
involv
format
transient
coval
bond
catalyt
cy
residu
figur
interest
studi
kishor
kumar
et
al
first
util
idea
synthes
small
librari
compound
activ
class
inhibitor
compris
one
metabromo
substitut
aryl
ring
along
anoth
one
optim
substitut
function
inhibitor
place
activ
site
cleft
cathepsin
l
metabromo
substitut
aryl
ring
occupi
site
thiosemicarbazon
motif
lie
near
activ
site
cystein
howev
motif
extend
captur
site
interact
place
arylalkyl
group
termin
nitrogen
thiosemicarbazon
inhibitori
potenc
complet
diminish
overal
class
inhibitor
show
good
select
cathepsin
b
exhibit
low
cytotox
test
human
cancer
cell
line
follow
studi
kishor
et
al
parker
et
al
expand
scope
thiosemicarbazon
scaffold
develop
divers
function
analog
exhibit
enhanc
inhibitori
potenc
promis
cellular
activ
still
retain
select
cathepsin
b
latest
studi
parker
et
al
strateg
transform
activ
inhibitor
limit
aqueou
solubl
watersolubl
prodrug
entri
tabl
phosphoryl
phenol
hydroxi
group
group
readili
hydrolyz
alkalin
phosphatas
render
activ
pharmacophor
phosphat
prodrug
exhibit
remark
increas
solubl
parent
drug
disintegr
aqueou
solut
even
prolong
exposur
physiolog
temperatur
furthermor
compound
show
signific
cytotox
normal
primari
huvec
cell
comparison
fdaapprov
cytotox
drug
doxorubicin
paclitaxel
prodrug
thu
far
shown
promis
desir
clinic
candid
author
propos
evalu
vivo
efficaci
preclin
setup
note
earlier
cathepsin
l
like
cystein
cathepsin
contain
inhibitori
propeptid
domain
span
activ
site
enzym
invers
direct
regular
substrat
bind
mode
chowdhuri
et
al
semin
studi
exploit
concept
examin
effect
seri
synthes
tripeptidyl
compound
mimick
cathepsin
l
inhibitori
propeptid
importantli
develop
tripeptidyl
motif
also
exhibit
nanomolar
potenc
howev
moder
truncat
fulllength
propeptid
drastic
lost
activ
notabl
fulllength
propeptid
show
select
cathepsin
k
potent
analog
seri
entri
tabl
demonstr
farimprov
select
author
investig
bind
mode
class
inhibitor
mean
cocryst
structur
molecular
model
reveal
arginin
residu
inhibitor
occupi
pocket
b
phenyl
alanin
residu
found
favor
hydrophob
interact
within
pocket
c
group
point
toward
pocket
methionin
residu
show
optim
interact
within
pocket
e
biphenyl
acetyl
group
extend
pocket
favor
interact
class
inhibitor
shown
resist
enzymedepend
hydrolysi
demonstr
revers
mode
enzym
inactiv
overal
inhibitor
class
provid
wealth
inform
inhibitor
bind
cathepsin
l
provid
gener
templat
develop
therapeut
candid
relev
enzym
well
effort
discov
small
molecul
inhibitor
cathepsin
l
myer
et
al
perform
high
throughput
screen
ht
nih
molecular
librari
small
molecul
repositori
mlsmr
identifi
oxadiazol
figur
potent
hit
compound
surprisingli
upon
synthesi
purif
put
inhibitori
lead
compound
complet
loss
activ
observ
author
investig
compound
integr
nih
mlsmr
librari
lcm
show
presenc
addit
impur
trace
back
activ
impur
author
hypothes
presenc
impur
result
acidcatalyz
ringopen
reaction
thiocarbaz
result
azapeptid
like
activ
pharmacophor
inhibit
enzym
via
acyl
activ
site
cy
valid
synthesi
azapeptid
perform
enzym
assay
stereoisom
newli
synthes
compound
entri
tabl
figur
inde
attenu
activ
cathepsin
l
ic
valu
nm
follow
studi
author
develop
seri
compound
structur
divers
perform
comput
analysi
recogn
basi
potent
enzym
inhibit
one
thiocarbaz
analog
develop
way
figur
show
improv
potenc
parent
compound
molecular
model
studi
perform
parent
compound
entri
tabl
complex
papain
indic
indol
motif
prefer
bound
subsit
nhboc
group
engag
favor
hydrophob
interact
within
subsit
anilid
extend
pocket
probe
import
thiocarbaz
moieti
author
synthes
compound
contain
oxocarbaz
entri
tabl
azapeptid
entri
tabl
motif
oxocarbaz
show
fairli
improv
ic
valu
nm
toward
cathepsin
l
wherea
azapeptid
best
modest
inhibitor
ic
consist
bind
mode
oxocarbaz
exert
similar
thiocarbaz
investig
molecular
model
studi
motif
oxocarbaz
show
fairli
improv
valu
nm
toward
cathepsin
l
wherea
azapeptid
best
modest
inhibitor
consist
bind
mode
oxocarbaz
exert
similar
thiocarbaz
investig
molecular
model
studi
separ
studi
shah
et
al
carri
thorough
enzymat
analysi
champion
thiocarbaz
compound
entri
tabl
show
timedepend
improv
inhibit
profil
valu
went
nm
preincub
cathepsin
l
h
lcm
kinet
analysi
enzymeinhibitor
complex
inhibit
rate
constant
kon
koff
bind
constant
ki
nm
demonstr
slowbind
kinet
revers
inhibit
select
member
enzym
famili
modest
interestingli
compound
inhibit
propag
malaria
parasit
plasmodium
falciparum
leishmania
major
exhibit
signific
toxic
human
aortic
endotheli
cell
zebrafish
although
thiocarbaz
motif
show
promis
inhibitori
scaffold
lack
reason
stabil
decompos
even
dmso
modest
inhibitori
activ
cellbas
assay
probabl
ceas
develop
scaffold
author
also
extend
studi
evalu
potenti
oxocarbaz
inhibitor
show
improv
valu
nm
upon
h
preincub
enzym
like
case
thiocarbaz
perform
enzym
kinet
analysi
enzymeinhibitor
complex
obtain
follow
paramet
inhibit
rate
constant
kon
koff
bind
constant
ki
nm
inhibitor
block
sarscov
nm
ebola
viru
nm
entri
human
embryon
kidney
hek
cell
process
util
cathepsin
lmediat
proteolysi
host
cell
infect
oxocarbaz
treat
hek
lysat
presenc
activitybas
cystein
cathepsin
probe
show
reduc
cathepsin
l
label
assess
westernblot
analysi
separ
studi
shah
et
al
carri
thorough
enzymat
analysi
champion
thiocarbaz
compound
entri
tabl
show
timedepend
improv
inhibit
profil
ic
valu
went
nm
preincub
cathepsin
l
h
lcm
kinet
analysi
enzymeinhibitor
complex
inhibit
rate
constant
k
k
bind
constant
k
nm
demonstr
slowbind
kinet
revers
inhibit
select
member
enzym
famili
modest
interestingli
compound
inhibit
propag
malaria
parasit
plasmodium
falciparum
ic
leishmania
major
ic
exhibit
signific
toxic
human
aortic
endotheli
cell
zebrafish
although
thiocarbaz
motif
show
promis
inhibitori
scaffold
lack
reason
stabil
decompos
even
dmso
modest
inhibitori
activ
cellbas
assay
probabl
ceas
develop
scaffold
author
also
extend
studi
evalu
potenti
oxocarbaz
inhibitor
show
improv
ic
valu
nm
upon
h
preincub
enzym
like
case
thiocarbaz
perform
enzym
kinet
analysi
enzymeinhibitor
complex
obtain
follow
paramet
inhibit
rate
constant
k
k
bind
constant
k
nm
inhibitor
block
sarscov
ic
nm
ebola
viru
nm
entri
human
embryon
kidney
hek
cell
process
util
cathepsin
lmediat
proteolysi
host
cell
infect
oxocarbaz
treat
hek
lysat
presenc
activitybas
cystein
cathepsin
probe
show
reduc
cathepsin
l
label
assess
westernblot
analysi
corrobor
result
obtain
viru
pseudotyp
infect
assay
overal
oxocarbaz
inhibitor
provid
promis
templat
exploit
also
render
new
direct
interven
sar
ebola
viru
infect
ubiquit
express
human
cathepsin
l
human
tissu
possess
signific
challeng
target
enzym
therapeut
develop
problem
exacerb
recent
find
altern
splice
isoform
could
exist
distinct
cellular
locat
eg
nucleu
cytosol
ecm
space
sever
uniqu
function
role
cathepsin
l
known
also
report
function
also
accomplish
member
cathepsin
famili
ie
function
redund
exampl
cathepsin
l
b
mediat
mutual
compensatori
role
inflammatori
respons
signal
pathway
regard
accur
function
cathepsin
l
must
first
determin
differ
cell
type
individu
consid
signific
invest
drug
develop
sinc
function
enzym
cathepsin
l
depend
primarili
activ
profil
given
activ
profil
differenti
process
cathepsin
l
isoform
may
differ
probe
capabl
report
accur
activ
statu
differ
cell
type
cellular
locat
anticip
advanc
understand
cathepsin
l
biolog
year
concept
activitybas
probe
abp
emerg
valuabl
chemic
biolog
tool
monitor
enzym
activ
express
profil
alon
cell
proteom
level
case
exist
coval
inhibitor
contain
recognit
motif
adopt
transform
abp
conjug
optim
detect
modal
includ
fluoresc
probe
affin
label
radiotrac
mani
other
figur
inde
use
abp
rather
establish
cathepsin
key
diagnost
marker
variou
diseas
condit
even
enabl
optic
surgic
navig
lead
improv
surgic
precis
follow
section
discuss
cathepsin
lselect
molecular
probe
develop
util
monitor
activ
thorough
overview
cathepsin
probe
develop
imag
purpos
could
found
elsewher
ubiquit
express
human
cathepsin
l
human
tissu
possess
signific
challeng
target
enzym
therapeut
develop
problem
exacerb
recent
find
altern
splice
isoform
could
exist
distinct
cellular
locat
eg
nucleu
cytosol
ecm
space
sever
uniqu
function
role
cathepsin
l
known
also
report
function
also
accomplish
member
cathepsin
famili
ie
function
redund
exampl
cathepsin
l
b
mediat
mutual
compensatori
role
inflammatori
respons
signal
pathway
regard
accur
function
cathepsin
l
must
first
determin
differ
cell
type
individu
consid
signific
invest
drug
develop
sinc
function
enzym
cathepsin
l
depend
primarili
activ
profil
given
activ
profil
differenti
process
cathepsin
l
isoform
may
differ
probe
capabl
report
accur
activ
statu
differ
cell
type
cellular
locat
anticip
advanc
understand
cathepsin
l
biolog
year
concept
activitybas
probe
abp
emerg
valuabl
chemic
biolog
tool
monitor
enzym
activ
express
profil
alon
cell
proteom
level
case
exist
coval
inhibitor
contain
recognit
motif
adopt
transform
abp
conjug
optim
detect
modal
includ
fluoresc
probe
affin
label
radiotrac
mani
other
figur
inde
use
abp
rather
establish
cathepsin
key
diagnost
marker
variou
diseas
condit
even
enabl
optic
surgic
navig
lead
improv
surgic
precis
follow
section
discuss
cathepsin
lselect
molecular
probe
develop
util
monitor
activ
thorough
overview
cathepsin
probe
develop
imag
purpos
could
found
elsewher
radiolabel
inhibitor
long
use
primari
mode
detect
activ
cystein
proteas
vitro
vivo
docherti
et
al
first
use
chloromethyl
inhibitor
contain
radioact
iodin
ityralalysargch
cl
detect
cathepsin
b
crude
granul
fraction
islet
cell
follow
studi
also
presum
identifi
cathepsin
l
insulin
secretori
granul
use
radioisotop
label
inhibitor
mechan
detect
involv
coval
modif
target
protein
show
distinct
band
upon
perform
autoradiographi
chloromethyl
contain
inhibitor
turn
nonselect
due
reactiv
toward
trypsin
serin
proteas
follow
discoveri
radioactivepeptidyldiazomethan
compound
entri
tabl
select
cystein
proteinas
inhibitor
mason
et
al
adopt
peptidyldiazomethan
scaffold
potent
inhibit
cathepsin
l
b
scaffold
show
improv
inhibit
profil
upon
iodin
demonstr
crawford
et
al
inhibitori
agent
transform
radiolabel
probe
via
incorpor
develop
probe
util
detect
cathepsin
l
b
kirstenvirustransform
knih
cell
incub
cellular
extract
follow
gel
electrophoresi
show
presenc
two
protein
band
kda
show
two
activ
form
cathepsin
l
activ
cathepsin
b
also
detect
around
kda
interestingli
pulsechas
experi
methioninelabel
protein
detect
two
separ
band
kda
kda
correspond
intracellular
inact
precursor
cathepsin
l
b
respect
indic
inact
precursor
protein
react
demonstr
uniqu
abil
quantifi
activ
protein
util
probe
activ
cathepsin
l
b
differ
human
tissu
well
lysosom
whole
cell
followup
studi
xing
et
al
develop
fmoc
tyralachn
entri
tabl
select
detect
cathepsin
l
b
cathepsin
exhibit
faster
rate
inactiv
toward
cathepsin
l
develop
compound
success
probe
amount
activ
cathepsin
l
b
differ
celllin
two
unknown
protein
also
got
label
certain
case
overal
probe
enabl
detect
activ
cathepsin
enzym
cellular
locat
therebi
advanc
knowledg
cathepsin
l
biolog
radiolabel
inhibitor
long
use
primari
mode
detect
activ
cystein
proteas
vitro
vivo
docherti
et
al
first
use
chloromethyl
inhibitor
contain
radioact
iodin
detect
cathepsin
b
crude
granul
fraction
islet
cell
follow
studi
also
presum
identifi
cathepsin
l
insulin
secretori
granul
use
radioisotop
label
inhibitor
mechan
detect
involv
coval
modif
target
protein
show
distinct
band
upon
perform
autoradiographi
chloromethyl
contain
inhibitor
turn
nonselect
due
reactiv
toward
trypsin
serin
proteas
follow
discoveri
radioactivepeptidyldiazomethan
compound
entri
tabl
select
cystein
proteinas
inhibitor
mason
et
al
adopt
peptidyldiazomethan
scaffold
potent
inhibit
cathepsin
l
b
scaffold
show
improv
inhibit
profil
upon
iodin
demonstr
crawford
et
al
inhibitori
agent
transform
radiolabel
probe
via
incorpor
develop
probe
util
detect
cathepsin
l
b
kirstenvirustransform
knih
cell
incub
cellular
extract
follow
gel
electrophoresi
show
presenc
two
protein
band
kda
show
two
activ
form
cathepsin
l
activ
cathepsin
b
also
detect
around
kda
interestingli
pulsechas
experi
methioninelabel
protein
detect
two
separ
band
kda
kda
correspond
intracellular
inact
precursor
cathepsin
l
b
respect
indic
inact
precursor
protein
react
demonstr
uniqu
abil
quantifi
activ
protein
util
probe
activ
cathepsin
l
b
differ
human
tissu
well
lysosom
whole
cell
followup
studi
entri
tabl
select
detect
cathepsin
l
b
cathepsin
exhibit
faster
rate
inactiv
toward
cathepsin
l
develop
compound
success
probe
amount
activ
cathepsin
l
b
differ
celllin
two
unknown
protein
also
got
label
certain
case
overal
probe
enabl
detect
activ
cathepsin
enzym
cellular
locat
therebi
advanc
knowledg
cathepsin
l
biolog
radiolabel
inhibitor
long
use
primari
mode
detect
activ
cystein
proteas
vitro
vivo
docherti
et
al
first
use
chloromethyl
inhibitor
contain
radioact
iodin
detect
cathepsin
b
crude
granul
fraction
islet
cell
follow
studi
also
presum
identifi
cathepsin
l
insulin
secretori
granul
use
radioisotop
label
inhibitor
mechan
detect
involv
coval
modif
target
protein
show
distinct
band
upon
perform
autoradiographi
chloromethyl
contain
inhibitor
turn
nonselect
due
reactiv
toward
trypsin
serin
proteas
follow
discoveri
radioactivepeptidyldiazomethan
compound
entri
tabl
select
cystein
proteinas
inhibitor
mason
et
al
adopt
peptidyldiazomethan
scaffold
potent
inhibit
cathepsin
l
b
scaffold
show
improv
inhibit
profil
upon
iodin
demonstr
crawford
et
al
inhibitori
agent
transform
radiolabel
probe
via
incorpor
develop
probe
util
detect
cathepsin
l
b
kirstenvirustransform
knih
cell
incub
cellular
extract
follow
gel
electrophoresi
show
presenc
two
protein
band
kda
show
two
activ
form
cathepsin
l
activ
cathepsin
b
also
detect
around
kda
interestingli
pulsechas
experi
methioninelabel
protein
detect
two
separ
band
kda
kda
correspond
intracellular
inact
precursor
cathepsin
l
b
respect
indic
inact
precursor
protein
react
demonstr
uniqu
abil
quantifi
activ
protein
util
probe
activ
cathepsin
l
b
differ
human
tissu
well
lysosom
whole
cell
followup
studi
entri
tabl
select
detect
cathepsin
l
b
cathepsin
exhibit
faster
rate
inactiv
toward
cathepsin
l
develop
compound
success
probe
amount
activ
cathepsin
l
b
differ
celllin
two
unknown
protein
also
got
label
certain
case
overal
probe
enabl
detect
activ
cathepsin
enzym
cellular
locat
therebi
advanc
knowledg
cathepsin
l
biolog
radiolabel
inhibitor
long
use
primari
mode
detect
activ
cystein
proteas
vitro
vivo
docherti
et
al
first
use
chloromethyl
inhibitor
contain
radioact
iodin
detect
cathepsin
b
crude
granul
fraction
islet
cell
follow
studi
also
presum
identifi
cathepsin
l
insulin
secretori
granul
use
radioisotop
label
inhibitor
mechan
detect
involv
coval
modif
target
protein
show
distinct
band
upon
perform
autoradiographi
chloromethyl
contain
inhibitor
turn
nonselect
due
reactiv
toward
trypsin
serin
proteas
follow
discoveri
radioactivepeptidyldiazomethan
compound
entri
tabl
select
cystein
proteinas
inhibitor
mason
et
al
adopt
peptidyldiazomethan
scaffold
potent
inhibit
cathepsin
l
b
scaffold
show
improv
inhibit
profil
upon
iodin
demonstr
crawford
et
al
inhibitori
agent
transform
radiolabel
probe
via
incorpor
develop
probe
util
detect
cathepsin
l
b
kirstenvirustransform
knih
cell
incub
cellular
extract
follow
gel
electrophoresi
show
presenc
two
protein
band
kda
show
two
activ
form
cathepsin
l
activ
cathepsin
b
also
detect
around
kda
interestingli
pulsechas
experi
methioninelabel
protein
detect
two
separ
band
kda
kda
correspond
intracellular
inact
precursor
cathepsin
l
b
respect
indic
inact
precursor
protein
react
demonstr
uniqu
abil
quantifi
activ
protein
util
probe
activ
cathepsin
l
b
differ
human
tissu
well
lysosom
whole
cell
followup
studi
entri
tabl
select
detect
cathepsin
l
b
cathepsin
exhibit
faster
rate
inactiv
toward
cathepsin
l
develop
compound
success
probe
amount
activ
cathepsin
l
b
differ
celllin
two
unknown
protein
also
got
label
certain
case
overal
probe
enabl
detect
activ
cathepsin
enzym
cellular
locat
therebi
advanc
knowledg
cathepsin
l
biolog
detect
agentsradionuclid
biotin
fluorophor
clickabl
acetylen
lanthanid
contain
dota
redcolor
code
photoactivat
benzoyl
group
quencher
code
blue
inhibit
gelhau
et
al
first
develop
biotinyl
demonstr
antiplasmodi
activ
use
cellbas
studi
sinc
biotinyl
compound
inhibit
plasmodi
proteas
falcipain
cathepsin
l
author
suggest
scaffold
could
util
develop
cellperm
nonradioact
reagent
select
label
enzym
involv
parasit
pathogen
later
vicik
et
al
adopt
motif
entri
tabl
develop
affin
label
probe
cathepsin
l
activ
aziridin
analog
irrevers
inactiv
enzym
via
coval
modif
discuss
previous
conjug
biotin
moieti
util
affin
pull
target
identif
isom
biotinyl
probe
incub
cathepsin
l
subject
gel
electrophoresi
electrotransf
membran
expos
streptavidinalkalin
phosphatas
conjug
strong
label
enzymeinhibitor
complex
observ
howev
enzym
treat
activ
sitedirect
competit
irrevers
cathepsin
inhibitor
prior
incub
label
diminish
clearli
demonstr
compet
activ
site
cathepsin
l
line
observ
desthiobiotinyl
analog
also
exhibit
trend
reduc
label
due
weaker
bind
affin
streptavidin
although
detect
agentsradionuclid
biotin
fluorophor
clickabl
acetylen
lanthanid
contain
dota
redcolor
code
photoactivat
benzoyl
group
quencher
code
blue
inhibit
gelhau
et
al
first
develop
biotinyl
demonstr
antiplasmodi
activ
use
cellbas
studi
sinc
biotinyl
compound
inhibit
plasmodi
proteas
falcipain
cathepsin
l
author
suggest
scaffold
could
util
develop
cellperm
nonradioact
reagent
select
label
enzym
involv
parasit
pathogen
later
vicik
et
al
adopt
motif
entri
tabl
develop
affin
label
probe
cathepsin
l
activ
aziridin
analog
irrevers
inactiv
enzym
via
coval
modif
discuss
previous
conjug
biotin
moieti
util
affin
pull
target
identif
isom
biotinyl
probe
incub
cathepsin
l
subject
gel
electrophoresi
electrotransf
membran
expos
streptavidinalkalin
phosphatas
conjug
strong
label
enzymeinhibitor
complex
observ
howev
enzym
treat
activ
sitedirect
competit
irrevers
cathepsin
inhibitor
prior
incub
label
diminish
clearli
demonstr
compet
activ
site
cathepsin
l
line
observ
desthiobiotinyl
analog
also
exhibit
trend
reduc
label
due
weaker
bind
affin
streptavidin
although
detect
agentsradionuclid
biotin
fluorophor
clickabl
acetylen
lanthanid
contain
dota
redcolor
code
photoactivat
benzoyl
group
quencher
code
blue
inhibit
gelhau
et
al
first
develop
biotinyl
demonstr
antiplasmodi
activ
use
cellbas
studi
sinc
biotinyl
compound
inhibit
plasmodi
proteas
falcipain
cathepsin
l
author
suggest
scaffold
could
util
develop
cellperm
nonradioact
reagent
select
label
enzym
involv
parasit
pathogen
later
vicik
et
al
adopt
motif
entri
tabl
develop
affin
label
probe
cathepsin
l
activ
aziridin
analog
irrevers
inactiv
enzym
via
coval
modif
discuss
previous
conjug
biotin
moieti
util
affin
pull
target
identif
isom
biotinyl
probe
incub
cathepsin
l
subject
gel
electrophoresi
electrotransf
membran
expos
streptavidinalkalin
phosphatas
conjug
strong
label
enzymeinhibitor
complex
observ
howev
enzym
treat
activ
sitedirect
competit
irrevers
cathepsin
inhibitor
prior
incub
label
diminish
clearli
demonstr
compet
activ
site
cathepsin
l
line
observ
desthiobiotinyl
analog
also
exhibit
trend
reduc
label
due
weaker
bind
affin
streptavidin
although
fluoresc
cathepsin
l
specif
degre
label
seen
cat
v
b
detect
agentsradionuclid
biotin
fluorophor
clickabl
acetylen
lanthanid
contain
dota
redcolor
code
photoactivat
benzoyl
group
quencher
code
blue
inhibit
gelhau
et
al
first
develop
biotinyl
demonstr
antiplasmodi
activ
use
cellbas
studi
sinc
biotinyl
compound
inhibit
plasmodi
proteas
falcipain
cathepsin
l
author
suggest
scaffold
could
util
develop
cellperm
nonradioact
reagent
select
label
enzym
involv
parasit
pathogen
later
vicik
et
al
adopt
motif
entri
tabl
develop
affin
label
probe
cathepsin
l
activ
aziridin
analog
irrevers
inactiv
enzym
via
coval
modif
discuss
previous
conjug
biotin
moieti
util
affin
pull
target
identif
isom
biotinyl
probe
incub
cathepsin
l
subject
gel
electrophoresi
electrotransf
membran
expos
streptavidinalkalin
phosphatas
conjug
strong
label
enzymeinhibitor
complex
observ
howev
enzym
treat
activ
sitedirect
competit
irrevers
cathepsin
inhibitor
prior
incub
label
diminish
clearli
demonstr
compet
activ
site
cathepsin
l
line
observ
desthiobiotinyl
analog
also
exhibit
trend
reduc
label
due
weaker
bind
affin
streptavidin
although
detect
agentsradionuclid
biotin
fluorophor
clickabl
acetylen
lanthanid
contain
dota
redcolor
code
photoactivat
benzoyl
group
quencher
code
blue
inhibit
gelhau
et
al
first
develop
biotinyl
demonstr
antiplasmodi
activ
use
cellbas
studi
sinc
biotinyl
compound
inhibit
plasmodi
proteas
falcipain
cathepsin
l
author
suggest
scaffold
could
util
develop
cellperm
nonradioact
reagent
select
label
enzym
involv
parasit
pathogen
later
vicik
et
al
adopt
motif
entri
tabl
develop
affin
label
probe
cathepsin
l
activ
aziridin
analog
irrevers
inactiv
enzym
via
coval
modif
discuss
previous
conjug
biotin
moieti
util
affin
pull
target
identif
isom
biotinyl
probe
incub
cathepsin
l
subject
gel
electrophoresi
electrotransf
membran
expos
streptavidinalkalin
phosphatas
conjug
strong
label
enzymeinhibitor
complex
observ
howev
enzym
treat
activ
sitedirect
competit
irrevers
cathepsin
inhibitor
prior
incub
label
diminish
clearli
demonstr
compet
activ
site
cathepsin
l
line
observ
desthiobiotinyl
analog
also
exhibit
trend
reduc
label
due
weaker
bind
affin
streptavidin
although
detect
agentsradionuclid
biotin
fluorophor
clickabl
acetylen
lanthanid
contain
dota
redcolor
code
photoactivat
benzoyl
group
quencher
code
blue
inhibit
gelhau
et
al
first
develop
biotinyl
demonstr
antiplasmodi
activ
use
cellbas
studi
sinc
biotinyl
compound
inhibit
plasmodi
proteas
falcipain
cathepsin
l
author
suggest
scaffold
could
util
develop
cellperm
nonradioact
reagent
select
label
enzym
involv
parasit
pathogen
later
vicik
et
al
adopt
motif
entri
tabl
develop
affin
label
probe
cathepsin
l
activ
aziridin
analog
irrevers
inactiv
enzym
via
coval
modif
discuss
previous
conjug
biotin
moieti
util
affin
pull
target
identif
isom
biotinyl
probe
incub
cathepsin
l
subject
gel
electrophoresi
electrotransf
membran
expos
streptavidinalkalin
phosphatas
conjug
strong
label
enzymeinhibitor
complex
observ
howev
enzym
treat
activ
sitedirect
competit
irrevers
cathepsin
inhibitor
prior
incub
label
diminish
clearli
demonstr
compet
activ
site
cathepsin
l
line
observ
desthiobiotinyl
analog
also
exhibit
trend
reduc
label
due
weaker
bind
affin
streptavidin
although
modest
bind
affin
k
cathepsin
l
exert
select
cathepsin
b
certainli
affin
label
techniqu
serv
abp
cathepsin
l
also
provid
premis
develop
aziridinebas
chemic
tool
function
proteom
although
coval
modifi
protein
vastli
exploit
chemic
tool
target
identif
function
proteom
photoaffin
probe
offer
uniqu
mode
action
bind
protein
noncoval
affin
base
sole
noncoval
interact
first
form
nonselect
coval
bond
closest
amino
acid
residu
upon
irradi
torkar
et
al
took
advantag
techniqu
develop
first
photoaffinitybas
probe
entri
tabl
detect
activ
cathepsin
l
select
member
famili
photoaffinitybas
probe
design
base
exist
peptidyl
acetyloxymethyl
keton
aomk
known
coval
modifi
cystein
proteas
design
aomk
group
cterminu
replac
short
di
ethylen
glycol
moieti
increas
aqueou
solubl
alter
charact
inhibitor
irrevers
revers
one
probe
compris
lysin
residu
strateg
place
append
fluoresc
group
detect
photoactivat
benzoylphenylalanin
amino
acid
place
accommod
pocket
cathepsin
l
develop
probe
detect
recombin
cathepsin
l
upon
incub
subsequ
irradi
min
nm
demonstr
sdspage
protein
band
becam
invis
enzym
incub
known
cathepsin
l
inhibitor
respect
prior
probe
treatment
probe
also
show
preferenti
select
toward
cathepsin
l
compar
two
fluorescentbas
probe
probe
exhibit
remark
select
cathepsin
l
cathepsin
lightmedi
label
experi
recombin
protein
rel
label
percentag
cathepsin
b
k
cathepsin
insignific
except
cathepsin
v
closest
homolog
cathepsin
l
rel
cathepsin
l
interestingli
glioma
cell
extract
present
cathepsin
l
detect
probe
howev
cell
extract
treat
recombin
cathepsin
l
ad
extern
subject
label
experi
probe
select
detect
desir
protein
complex
proteom
mechan
protein
label
attribut
put
bond
format
benzophenon
nonconserv
site
cathepsin
l
although
develop
probe
lack
cellpenetr
author
envis
techniqu
might
diagnost
prognost
valu
cathepsin
l
overexpress
high
malign
tissu
although
sever
fluorescentbas
molecular
probe
report
cystein
cathepsin
superior
twophotonbas
onephoton
base
imag
techniqu
inspir
na
et
al
develop
probe
better
cellular
imag
profil
notabl
twophoton
fluoresc
imag
techniqu
provid
increas
tissu
penetr
depth
reduc
photobleach
lower
tissu
autofluoresc
author
first
fabric
microarray
differ
peptidyl
aldehyd
screen
gfplabel
cathepsin
l
enzym
led
identif
two
inhibitori
hit
potent
inactiv
enzym
ic
valu
nm
lead
inhibitor
structur
modifi
includ
twophoton
dye
pyrimidin
deriv
posit
b
dispers
red
dye
fluoresc
quencher
place
aldehyd
moieti
result
imag
probe
entri
tabl
one
exampl
show
timedepend
increas
fluoresc
signal
treat
cell
lysat
mammalian
liver
cancer
celllin
known
overexpress
cystein
cathepsin
enhanc
fluoresc
signal
due
releas
quencher
upon
success
proteolyt
cleavag
furthermor
assess
suitabl
imag
agent
live
cell
cell
incub
probe
subject
livecel
imag
analysi
strong
fluoresc
signal
endolysom
compart
disappear
complet
cell
pretreat
valid
target
specif
probe
probe
develop
use
cathepsin
l
model
enzym
like
lack
specif
perhap
interact
member
famili
still
howev
motif
could
potenti
util
develop
select
abp
target
respect
cathepsin
assess
activ
tissu
environ
propos
author
activitybas
probe
singl
photon
fluoresc
tag
success
util
function
analysi
target
protein
vitro
vivo
poreba
et
al
pursuit
develop
cathepsin
l
select
imag
agent
took
advantag
technolog
realiz
import
develop
select
cathepsin
l
substrat
bind
activ
site
enzym
homolog
protein
employ
hybrid
combinatori
substrat
librari
hycosul
technolog
provid
inform
optim
chemic
space
insid
enzym
activ
site
strateg
scan
divers
peptid
librari
contain
natur
unnatur
amino
acid
led
acquisit
panel
compound
desir
properti
potent
hit
discov
hycosul
technolog
optim
gain
select
cathepsin
identifi
effici
substrat
base
micha
menten
paramet
unfortun
chosen
peptid
substrat
transform
activitybas
probe
append
acyloxymethylketon
warhead
biotin
tag
show
crossreact
cathepsin
b
despit
biotinyl
probe
somewhat
compromis
select
author
still
assess
activitybas
label
profil
cell
expect
cathepsin
l
label
primarili
observ
minor
amount
cathepsin
b
optim
swap
biotin
arg
cy
bzl
entri
tabl
group
carri
next
newli
develop
fluoresc
abp
show
enhanc
select
comparison
pancathepsin
probe
panel
recombin
cathepsin
cathepsin
v
b
k
well
cellular
extract
deriv
cell
develop
probe
serv
effect
imag
agent
cellular
cathepsin
l
activ
human
breast
cancer
cell
incub
h
select
probe
start
reced
longer
incub
time
import
optim
probe
concentr
timecours
reaction
evid
experi
interestingli
detect
activ
cathepsin
l
procathepsin
l
certainli
signifi
effect
develop
probe
activitybas
probe
author
examin
coloc
probe
cathepsin
l
b
cell
treat
cell
respect
cathepsin
antibodi
perform
quantit
pixel
analysi
set
fluoresc
microscopi
imag
support
previou
observ
highest
weight
coloc
coeffici
obtain
cathepsin
l
cathepsin
b
develop
compound
certainli
harbor
key
trait
effect
activitybas
probe
author
duli
envis
signific
deciph
cathepsin
l
biolog
come
year
note
fluorescencebas
imag
probe
success
develop
gain
access
unknown
function
cathepsin
enzym
howev
bulki
often
multipl
charg
associ
fluorophor
andor
quencher
structur
probe
like
render
poorli
cellperm
reduc
target
affin
address
issu
dana
et
al
adopt
previous
report
peptidyl
vinylsulfon
inhibitor
highli
potent
select
coval
irrevers
inhibitor
cathepsin
l
discuss
section
tactic
append
small
alkynyl
group
paraposit
cbz
group
led
develop
clickabl
tagless
activitybas
probe
catabp
cathepsin
l
retain
key
desir
trait
ie
cell
permeabl
charg
profil
molecular
weight
potenc
select
profil
strategi
elimin
requir
includ
bulki
charg
fluorophorequench
moieti
probe
one
inher
advantag
approach
label
perform
live
cellular
environ
high
effici
cell
lysi
label
cathepsin
l
quantifi
perform
click
chemistri
protocol
fluoresc
azid
contain
dye
resolv
protein
use
gelelectrophoresi
directli
scan
gel
fluoresc
signal
anticip
develop
probe
entri
tabl
exhibit
rapid
inactiv
kinet
retain
select
cathepsin
l
label
recombin
activ
cathepsin
l
activitydepend
manner
heatdenatur
treat
cathepsin
l
show
label
subject
ident
label
protocol
massspectrometr
analysi
enzymeprob
complex
conclud
probe
activesit
direct
coval
modifi
catalyt
cy
residu
inactiv
sinc
probe
develop
intent
captur
activ
cathepsin
l
vivo
human
live
cell
cultur
probe
test
cytotox
cell
cytotox
observ
cell
even
concentr
high
incub
cell
overexpress
cathepsin
l
attenu
intracellular
cathepsin
l
activ
dosedepend
manner
demonstr
livecel
imag
wound
heal
assay
final
also
interf
hatch
process
postfertil
zebrafish
embryo
valid
probe
vivo
activ
notabl
cathepsin
l
serv
key
regul
hatch
process
conclus
demonstr
mani
desir
attribut
good
probe
anticip
find
extens
applic
probe
cathepsin
l
function
cell
divers
origin
although
fluorophorescontain
molecul
appreci
use
imag
probe
commonli
use
fluorophor
often
suffer
spectral
overlap
limit
number
target
analyz
concomitantli
address
issu
poreba
et
al
recent
develop
proteaseselect
lanthanidelabel
probe
compat
mass
cytometri
allow
subsequ
analysi
mass
imag
mass
cytometri
imc
metaltag
time
flight
activitybas
probe
tof
allow
determin
cellular
activ
locat
three
lysosom
proteas
thu
use
cathepsin
l
b
legumain
model
system
elegantli
craft
activitybas
probe
incorpor
proteaseselect
peptid
sequenc
specif
enzym
recognit
b
acyloxymethylketon
electrophil
warhead
trap
target
enzym
c
dodecanetetraacet
acid
dota
metal
chelat
tether
peptid
sequenc
via
linker
entri
tabl
incorpor
three
differ
lanthanid
tb
lu
gd
mixtur
natur
occur
six
isotop
valid
approach
evalu
influenc
isotop
enzym
bind
specif
newli
develop
probe
exert
promis
select
toward
recombin
proteas
proteas
cancer
cell
line
author
abl
simultan
detect
activ
proteas
cell
moreov
proteasespecif
probe
exert
similar
label
effici
cell
regardless
metal
counterpart
reinforc
compat
class
probe
cytometrylabel
agent
extend
investig
cell
nonadher
monocytelik
cell
line
express
cathepsin
b
l
contain
low
level
legumain
enzym
probe
treat
show
clear
label
cathepsin
b
l
detect
activ
legumain
find
consist
transcript
data
final
develop
probe
allow
detect
activom
cathepsin
l
b
legumain
peripher
blood
mononuclear
cell
pbmc
also
enabl
categor
nk
cell
two
distinct
popul
base
proteas
activom
level
strategi
unlik
mani
exist
technolog
thu
allow
simultan
detect
target
proteas
therebi
provid
holist
understand
activom
certainli
merit
futur
develop
tofbas
probe
multiplex
enzym
activ
detect
inhibit
cathepsin
l
continu
emerg
forefront
drug
develop
sever
human
diseas
yet
inhibitori
agent
target
cathepsin
l
advanc
clinic
trial
inhibitor
cathepsin
b
current
evalu
clinic
trial
recent
failur
odanacatib
cathepsin
k
inhibitor
osteoporosi
late
stage
clinic
trial
made
pharmaceut
industri
wari
target
cathepsin
key
challeng
remain
gain
inhibitor
select
respect
member
cathepsin
direct
target
cell
type
select
function
perturb
ubiquit
express
profil
function
cathepsin
l
individu
cell
type
must
precis
defin
first
especi
import
sinc
sever
isoform
cathepsin
l
report
distinct
cellular
locat
activ
function
profil
individu
cell
type
still
remain
poorli
document
recent
develop
cathepsin
inhibitor
probe
significantli
advanc
understand
cathepsin
l
function
normal
diseas
cell
effort
need
develop
isoformselect
reagent
advanc
perhap
new
alloster
modul
cathepsin
l
enzym
explor
exploit
precis
target
fortun
sever
structur
coordin
cathepsin
l
enzym
form
divers
set
complex
ligand
without
avail
tabl
could
aid
develop
isoformselect
inhibitori
probe
enabl
research
assess
contextspecif
need
target
cathepsin
l
differ
cellular
state
recent
year
diseaseassoci
proteas
activat
prodrug
gain
much
recognit
garner
breakthrough
therapi
area
antibodydrug
conjug
adc
major
adc
construct
tether
cytotox
drug
antibodi
via
proteasesensit
modul
target
deliveri
cathepsin
bspecif
modul
exampl
success
implement
role
led
develop
fda
approv
therapi
exampl
brentuximab
vedotin
adcetri
relaps
refractori
hodgkin
lymphoma
addit
proteas
cleavabl
prodrug
strategi
also
inspir
develop
cathepsin
b
select
probe
even
enabl
realtim
monitor
drug
releas
interestingli
ueki
et
al
slightli
maneuv
approach
acquir
prodrug
get
serial
activ
histon
deacetylas
hdac
cathepsin
l
subsequ
deliv
cytotox
payload
puromycin
cancer
cell
strategi
thu
enabl
select
target
cancer
cell
specif
high
hdac
cathepsin
l
activ
taken
togeth
develop
sure
lay
foundat
develop
futur
cathepsin
lbase
therapi
much
excit
remain
new
cathepsin
l
function
continu
emerg
specif
cell
type
come
year
xray
xray
xray
xray
xray
xray
xray
xray
xray
xray
fund
skp
grate
acknowledg
financi
support
nation
scienc
foundat
nsf
grant
work
acknowledg
author
also
wish
thank
senthil
perum
provid
critic
feedback
prepar
manuscript
author
declar
conflict
interest
